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General introduction and outline of the thesis
Laryngeal carcinoma
The estimated number of new patients presenting with laryngeal cancer in the 
Netherlands is around 700 per year [1]. The disease is more prevalent in males than 
females with a factor 7:1. While the incidence in men is decreasing, a stabilization is 
observed in women. A clear association has been made with smoking, excess alcohol 
ingestion, and more recently human papilloma virus [2,3]. 
The larynx is divided into the following three anatomical regions:
	 The supraglottic larynx includes the epiglottis, false vocal cords, ventricles, 
aryepiglottic folds, and arytenoids.
	 The glottis includes the true vocal cords and the anterior and posterior 
commissures.
	 The subglottic region begins 1 cm below the true vocal cords and extends, 
depending on definitions, to the lower border of the cricoid cartilage or the first 
tracheal ring. 
The supraglottic area is rich in lymphatic drainage. After penetrating the pre-epiglottic 
space and thyrohyoid membrane, lymphatic drainage is initially to the jugulodigastric 
and midjugular nodes. The true vocal cords are devoid of lymphatics. Extension 
above or below the cords may, however, lead to lymph node involvement. Primary 
subglottic cancers drain through the cricothyroid and cricotracheal membranes to the 
pretracheal, paratracheal, and inferior jugular nodes, and occasionally to mediastinal 
nodes. 
Squamous cell carcinoma is by far the most prevalent histopathological diagnosis. 
Two-thirds of the laryngeal cancers are located at glottic level, one third at supraglottic 
level and the subglottic localization is very rare [1]. Men have more glottic tumors (64%), 
and women more supraglottic tumors (54%) [1]. Because of persistent hoarseness, 
the majority of glottic tumors is diagnosed at an early stage (stage I: 60%; stage II: 
29%) [1]. Atypical symptoms at presentation can explain the more advanced stage 
(stage III: 23%; stage IV: 44%) of supraglottic tumors at diagnosis [1].  
Optimal functional larynx preservation is the main goal when treating patients with 
laryngeal cancer. For early stages, treatment comprises (laser) surgery or radiotherapy 
with excellent long-term results [4]. Since the landmark trial, conducted by the 
Department of Veterans Affairs Laryngeal Cancer Study Group, demonstrated that 
induction chemotherapy followed by definitive radiotherapy did not compromise 
survival when compared to initial laryngectomy, organ-sparing approaches became 
502026-L-sub01-bw-Janssens
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preferred treatment for the majority of patients with advanced laryngeal cancer [5]. In 
the subsequent randomized Radiation Therapy Oncology Group 91-11 trial, the 5 
year local- and loco-regional control rate in patients treated with radiotherapy and 
concurrent cisplatin (71% and 68%) differed significantly from that for patients given 
induction chemotherapy followed by radiotherapy (58% and 55%) or conventional 
fractionated radiotherapy alone (54% and 51%) [6]. This means that still a significant 
subset of patients with advanced laryngeal cancer will develop loco-regional disease 
recurrence. Tumor-cell repopulation and hypoxia (the lack of oxygen) are 
important mechanisms of resistance that can cause therapy failure. 
Tumor-cell repopulation 
In squamous-cell carcinomas, the probability of local tumor control decreases as 
the overall treatment time of radiotherapy increases without a change in the radiation 
dose [7,8]. This relation is explained by an increase in the net production of clonogenic 
tumor cells during radiotherapy. Although during a course of radiotherapy the number 
of tumor cells with clonogenic potential is greatly reduced, cells that survive are 
triggered to repopulate more effectively [8]. To counteract the clonogenic repopulation 
during therapy, overall treatment time is reduced by giving the same total radiation 
dose with several fractions per day. This strategy is called accelerated fractionated 
radiotherapy. However, there is a limit to this acceleration because rapidly renewing 
normal tissues, such as mucosa, also rely on repopulation for the repair of tissue 
integrity after radiation damage [9]. There is now evidence from a Cochrane Systematic 
Review that accelerated radiotherapy without total dose reduction for patients with 
head-and-neck cancer, improved loco-regional tumor control at 5 years by 7.3% 
compared to conventional radiotherapy [10]. Successful studies generally used 
schedules with a reduced total treatment time of 5.0 to 5.5 weeks and an unchanged 
total dose of around 70 Gy. 
Hypoxia
Tumor-cell hypoxia is another well-recognized cause of resistance to radiation. 
Oxygen mediates the biological effects of ionizing radiation, and the response of 
cells to radiation depends strongly on the availability of oxygen. Typically, hypoxic 
cells are 2.5-3.0 times more radioresistant than well-oxygenated cells [11]. In the 
majority of solid tumors there is some imbalance between oxygen delivery and 
oxygen consumption, resulting in hypoxia [12]. The transport of oxygen to cells relies 
on blood perfusion and diffusion through the tissues. However, a chaotic vascular 
system impedes delivery of oxygen to the respiring neoplastic cells in solid tumors 
[13]. The consequences of these abnormalities are impaired blood perfusion and 
increased diffusion distances leading to a large temporal and spatial variability in 
tumor oxygenation. 
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Hypoxia also promotes more aggressive tumor behavior. Hypoxia is a powerful trigger 
for changes in gene expression and associated changes in the micro-environment. 
Due to these changes, clonogenic cells with increased adaptation to hypoxia are 
stimulated, driving the tumor towards a more malignant phenotype [14]. 
ARCON 
ARCON, acronym for accelerated radiotherapy with carbogen and nicotinamide, has 
been developed to counteract tumor-cell repopulation and hypoxia, both mechanisms 
of radiotherapy resistance. To limit clonogenic repopulation during therapy, the 
overall duration of radiotherapy is reduced from 7 weeks to 5.5 weeks, by delivering 
two fractions per day during part of the treatment. This accelerated radiotherapy is 
combined with inhalation of a hyperoxic gas (carbogen: 95-98% oxygen + 2-5% 
carbon dioxide) to decrease diffusion-limited hypoxia, and nicotinamide, a vasoactive 
agent, to decrease perfusion-limited hypoxia (Figure). 
Preclinical studies have been done to test the enhancing effects of the three components 
of ARCON in experimental mouse tumors and normal tissues. Phase 1 and 2 clinical 
trials have shown feasibility, tolerability and promising results of ARCON. More recently, 
a phase III trial for larynx carcinoma was completed which is subject of this thesis. 
Carbogen 
Raising arterial partial pressure of oxygen (pO2) by inhalation of hyperoxic gases is 
the most effective way to decrease diffusion-limited hypoxia. A small fraction of carbon 
dioxide was added to oxygen to increase the respiratory drive, to induce vasodilatation 
Figure  The concept of ARCON therapy.
Accelerated Radiotherapy CarbOgen 
(98% O2 + 2% CO2) 
Nicotinamide 
Diffusion-limited hypoxia Perfusion-limited hypoxia 
Occluded blood vessel 
Clonogenic Repopulation 
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but also for the improved oxygen delivery from blood to the tissues by a right-shift of 
the hemoglobin-oxygen dissociation curve. However, studies investigating the radio-
sensitizing effect of the addition of carbon dioxide to oxygen remain controversial 
[15,16]. The increase of the oxygen diffusion distance with inhalation of carbogen is 
best demonstrated by immuno-histochemical studies [17]. Irreversible intracellular 
binding occurs with nitroimidazoles, like pimonidazole, at tissue pO2 below 10 mmHg. 
The areas with hypoxic-marker binding become smaller with inhalation of carbogen 
and distances from vessels to hypoxia increase. Animal and human studies showed 
that a carbogen prebreathing time of 5 minutes was required before optimum tumor 
oxygenation occurred and the maximum sensitizing effect was achieved [15;18; 19]. 
Nicotinamide 
Nicotinamide is the amide derivate of vitamin B3 and has been studied for its radio-
sensitizing properties [20;21]. It is likely to act by decreasing perfusion-limited tumor 
hypoxia through prevention of intermittent vascular shutdown. Additional effects on 
tumor metabolism are thought to be possible as well [22]. Nicotinamide is converted 
to nicotinamide adenine dinucleotide (NAD+). Increased concentrations of NAD+ would 
lead to stimulation of many metabolic processes, including oxidative metabolism and 
glycolysis, with shifts in the oxygen consumption rate and acid-base balance. These 
effects could then have secondary effects on tumor blood flow and tissue pO2. 
For the radiosensitizing effect, a plasma concentration of 700 µmol/L (equivalent to 
an oral dose of 80 mg/kg) is required.  However, daily administration of this dose over 
a course of 5-7 weeks caused nausea and vomiting with discontinuation of intake in 
a large proportion of patients [23]. A reduction in peristalsis due to interaction with the 
gastro-intestinal smooth muscle, was the reason for the gastro-intestinal side-effects 
[24]. Compliance significantly improved with a reduction in dose to 60 mg/kg, given 
1-2 hours before radiotherapy and domperidone as anti-emetic profylaxis [25]. 
Preclinical studies 
In mouse mammary tumors, Rojas et al. observed an enhancement ratio of 1.19 for 
accelerated radiotherapy compared to conventional radiotherapy [26]. When carbogen 
was added to the accelerated regimen, a further enhancement was seen (ratio: 1.71). 
Finally, the combination of accelerated radiotherapy, carbogen, and nicotinamide 
resulted in an enhancement ratio of 1.91, indicating that with ARCON the same effect 
could be achieved as with conventional radiotherapy but with a radiation dose almost 
50% lower.  
502026-L-sub01-bw-Janssens
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While enhancement ratios of 1.0-2.4 are observed for murine tumors, enhancement 
ratios of the normal tissues are much lower (ratio 1.0-1.2) [27-31]. This indicates that, 
potentially, a significant therapeutic gain can be obtained with the ARCON approach. 
Clinical studies 
In the early 1990s, the first feasibility and toxicity studies with ARCON were done at 
Mount Vernon Hospital in the UK, shortly followed by other centers and the European 
Organisation for Research and Treatment of Cancer (EORTC) [32,33]. The initial phase I 
and II studies introduced ARCON in consecutive stages to analyze the feasibility and 
toxic effects of each component. The largest experience with ARCON is in patients 
with head and neck cancer, a disease with well-documented existence of hypoxia 
and tumor-cell repopulation [8;34;35]. In general, there was an increase in early mucosal 
and skin reactions observed with accelerated radiotherapy, mainly manifested as a 
delayed recovery with longer healing times [36]. Although the absolute number was 
small, an increased rate of patients with mandibular necrosis was observed [37;38]. 
Only the study of Kaanders et al. was large enough to allow conclusions about tumor 
response [37]. A group of 215 patients with advanced tumors (mainly T3 or T4) of 
the larynx, hypopharynx, oropharynx, and oral cavity were treated with accelerated 
radiotherapy (64-68 Gy in fractions of 2 Gy over 36-38 days, 2 fractions per day 
during the last 1.5 weeks) combined with carbogen and nicotinamide. Local control 
rates were 80% for laryngeal, 60% for hypopharyngeal, 87% for oropharyngeal, and 
29% for oral-cavity tumors. The high local control rate for advanced laryngeal 
cancers, approaching the results reported for T1 and T2 lesions, supported the 
concept of increased susceptibility of tumors to the biologically based approach of 
ARCON, offering excellent possibilities for organ preservation. Interestingly, T-stage 
had no prognostic significance, assuming that biological factors are more important 
predictors of treatment outcome.
Patient selection for ARCON
Between tumors of the same site and histology, large heterogeneity in biological 
characteristics exists. Identification of proliferative activity and oxygenation status in 
tumors is a logic approach to select candidates for ARCON.
In head and neck cancer a high proliferation index is correlated with aggressive tumor 
characteristics and poor outcome in numerous studies [39]. There are several 
indicators of the proliferation rate of tumors like growth fraction, a specific phase of 
the cell cycle or the cell cycle time. A widely used endogenous immunohistochemical 
marker is Ki-67. Recently, it was demonstrated in a large cohort of patients with 
advanced laryngeal cancer treated in the phase III ARCON study that node positive 
patients had a higher Ki-67 labeling index compared to node negative patients. In the 
502026-L-sub01-bw-Janssens
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group of patients treated with AR alone, high Ki-67 labeling index was associated 
with increased regional and distant metastasis formation whereas this was not 
observed in patients treated with ARCON [40]. The fact that accelerated radiotherapy 
does not correct for the negative prognostic value of Ki-67 while the addition of 
hypoxic modification does, does suggest a mutual relationship between proliferation 
and hypoxia. 
The gold standard method to measure pO2 is the use of Eppendorf polarographic 
electrodes [41]. However, the invasive and technically demanding nature of the 
technique is not attractive for routinely use. For this reason, exo- and endogenous 
hypoxia marker assays, detectable by immunohistochemistry, and more recently 
PET-tracers depicting hypoxia are more relevant in clinical use. The exogenous 
marker Pimonidazol can be administered intravenously and binds to viable hypoxic 
cells. In head and neck cancer a correlation was found between the degree of 
hypoxia, estimated by pimonidazol binding, and the loco-regional control and 
event-free survival [42;43]. In a group of 38 patients with head and neck cancers from 
different subsites, Kaanders et al. demonstrated that loco-regional control was 
significantly lower for patients with high pimonidazol binding levels (hypoxic tumors). 
However, this association disappeared in the subgroup of patients treated with 
ARCON [42]. A method not relying on injected markers to quantify hypoxia is the 
use of endogenous markers. Endogenous markers, like hypoxia-inducible factor 
(HIF), carbonic anhydrase IX (CA-IX) or glucose transporters (GLUTs) are proteins 
upregulated under hypoxic conditions. No single endogenous marker for head and 
neck cancer has consistently demonstrated strong prognostic power in clinical 
practice [44-46]. Attempts to combine various markers to create a hypoxia-prognostic 
profile are with moderate success [47,48]. In the field of PET-imaging, multiple hypoxia- 
related tracers have been tested during the years [49]. Among the various PET tracers 
synthesized, 18F-Misonidazole (MISO) and 18F-Fluoroazomycin arabinoside (FAZA) 
are the most commonly used. A major advantage of hypoxia imaging by PET is the 
geographic distribution of hypoxia within the tumor volume and its evolution during 
treatment. After co-registration of molecular imaging with radiotherapy CT- or MR- 
imaging, customized heterogeneous dose distributions can be generated with dose 
escalation to areas of hypoxia in order to improve loco-regional control [50;51]. 
Response measuring early during radiotherapy can discriminate good-responders 
from poor-responders and also result into treatment adaptation [52;53].
502026-L-sub01-bw-Janssens
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Outline of the thesis 
A 2-year local control rate of 92%, observed in 62 patients with stage III-IV laryngeal 
cancer treated in the phase II study, prompted a multicenter phase III study [54]. 
From 2001 until 2008, 345 patients with cT2-4 laryngeal cancer were randomly 
assigned to accelerated radiotherapy or accelerated radiotherapy combined with 
carbogen breathing and nicotinamide. This thesis reports on outcome, toxicity profile, 
role of anemia, impact of tumor volume and health-related quality-of-life (HRQoL).
Two-years after inclusion of the last patient, general outcome of the phase III trial is 
analyzed and reported in Chapter 2. A translational side-study, using the exogenous 
hypoxic marker pimonidazole, addresses the issue of selecting patients based on 
the oxygenation status. 
The potential price of treatment intensification is an increase of toxicity. Chapter 3 
reports on the acute toxicity observed during and after radiotherapy. Skin, mucosa 
and mucosa-related symptoms as well as compliance are compared between AR 
and ARCON. 
Anemia is associated with poor tumor control. Results from the phase II study 
demonstrated that ARCON can correct this adverse outcome in patients with head 
and neck cancer. In Chapter 4, the impact of ARCON on a subgroup of patients 
presenting with anemia is investigated. 
Retrospective studies indicate that larger tumor volume is a strong prognostic 
indicator for poor tumor control after (chemo)radiotherapy for laryngeal cancer. The 
impact of tumor volume on the outcome of patients with locally advanced laryngeal 
cancer treated in the phase III ARCON trial is reported in Chapter 5. 
Proper knowledge of HRQoL is equally essential to understand the real benefit of a 
new regimen. HRQoL is assessed using the European Organisation for Research 
and Treatment of Cancer (EORTC) HRQoL Questionnaire-C30 (QLQ-C30) and the 
Head & Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy 
and at 6, 12, and 24 months post-baseline. Results are discussed in Chapter 6.  
A general discussion, based on the abovementioned chapters, is given in Chapter 7. 
Chapters 8 and 9 provide a summary of the work in English and Dutch. 
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Summary 
Purpose
To report the results from a randomized trial comparing Accelerated Radiotherapy 
(AR) with Accelerated Radiotherapy plus Carbogen and Nicotinamide (ARCON) in 
laryngeal cancer.
Patients and Methods
Patients with cT2-4 squamous cell laryngeal cancer were randomized to AR (68 Gy 
within 36-38 days) or ARCON (AR plus carbogen inhalation and nicotinamide). To limit 
the risk of laryngeal necrosis, ARCON patients received 64 Gy on the laryngeal 
cartilage. The primary endpoint was local control. Secondary endpoints were regional 
control, larynx preservation, toxicity, disease-free survival and overall survival. In a 
translational side study the hypoxia marker pimonidazole was used to assess the 
oxygenation status in tumor biopsies.  
Results 
From 04-2001 to 02-2008, 345 patients were accrued. After a median follow-up of 44 
months, local tumor control rate at 5 years was 78% for AR versus 79% for ARCON 
(P=.80) with corresponding larynx preservation rates of 84% and 87% (P=.48). The 
5-year regional control was significantly better with ARCON (93%) compared to AR 
(86%, P=.04). The improvement in regional control was specifically observed in 
patients with hypoxic tumors and not in patients with well-oxygenated tumors (100% 
versus 55% respectively, P=.01). AR and ARCON produced equal levels of toxicity.
Conclusions 
Despite lack of benefit in local tumor control for advanced laryngeal cancers, a 
significant gain in regional control rate, with equal levels of toxicity, was observed in 
favor of ARCON. The poor regional control of patients with hypoxic tumors is 
specifically countered by ARCON treatment.
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Introduction
Functional larynx preservation is a main goal when treating patients with loco-regional 
advanced laryngeal cancer.1,2 The combination of radiotherapy with concurrent 
cisplatin demonstrated better larynx preservation and loco-regional control compared 
to conventional fractionated radiotherapy alone.2 However, conventional fractionated 
radiotherapy is currently not considered the optimal strategy for head and neck 
cancer. Based on accomplishments of radiobiological research, new approaches in 
clinical radiotherapy have been developed to improve treatment outcome.
In head and neck cancer, tumor cell repopulation and tumor hypoxia are known 
factors determining radiation response. Accelerated Radiotherapy plus Carbogen 
and Nicotinamide (ARCON) is a strategy to counteract these resistance mechanisms.3 
To limit clonogenic repopulation during therapy, the overall duration of radiotherapy 
is reduced by delivering multiple fractions per day. This approach, referred to as 
accelerated fractionation (AR), has demonstrated superior loco-regional control rates 
in head and neck cancer.4,5,6 ARCON combines accelerated radiotherapy with the 
inhalation of carbogen (98% O2 + 2% CO2) to decrease diffusion-limited hypoxia and 
the administration of nicotinamide, a vasoactive agent, to decrease perfusion-limited 
hypoxia.7,8,9,10,11,12 Phase I and II trials have shown the feasibility and tolerability of 
ARCON for head and neck cancer and have produced promising results in terms of 
tumor control.13,14,15 A favorable 5-year local control rate of 80% was obtained in a 
series of 79 T3 and T4 larynx carcinomas.14 
This provided the basis for a multicenter trial randomizing patients with cT2-4 
laryngeal cancer between AR and ARCON, of which the results are reported here. 
Data from this study on acute toxicity and compliance have been published recently.16 
Additionally, in a translational side study the value of a tumor hypoxia assay to predict 
response to ARCON was assessed. For this purpose pimonidazole was used, a 
bioreductive chemical probe that forms protein adducts in viable hypoxic cells and 
can be visualized in tumor biopsies by immunofluorescence.17 
Patients and methods
Study Design and Eligibility
This was an open-label, randomized phase III trial comparing AR with ARCON in 
laryngeal cancer. The trial was conducted under the auspices of the Dutch Head and 
Neck Cancer Group and the Dutch Cancer Society (KWF) in 7 centers in 2 countries 
(Table 1). 
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Table 1  Patient Demographics and Clinical Characteristics.
AR ARCON
N=174 N=171
Characteristics No. %  No.  %
Age (years)
Median 60 61
Range 38-88 41-84
Sex
male 136 78 142 83
female 38 22 29 17
Performance status
0 140 80 137 81
1 34 20 34 19
Site of the primary tumor (%)
Supraglottic 100 57 97 56
Glottic 74 43 74 44
T-stage (%)
T2 67 38 55 32
T3 80 46 95 56
T4 27 16 21 12
N-stage (%)
N0 117 67 116 68
N1 20 12 23 13
N2a 4 2 7 4
N2b 10 6 5 3
N2c 23 13 20 12
N3 0 0 0 0
Participating Institutions 
Radboud University Nijmegen Medical 
Centre, Nijmegen
75 43 76 44
University Medical Center Utrecht, Utrecht 38 22 39 23
VU University Medical Center, Amsterdam 21 12 20 12
University Medical Center Groningen, 
Groningen
15 9 13 8
Maastricht University Medical Centre, 
Maastricht
15 9 13 8
Leiden University Medical Center, Leiden 8 4 9 5
Mount Vernon Hospital, Northwood, UK 2 1 1 0
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Eligibility was assessed by a multidisciplinary head and neck oncology team. 
Diagnostic workup consisted of full history and physical examination, blood cell 
count and blood biochemistry, laryngoscopy under general anesthesia with biopsy 
taking, CT- or MR-imaging of the larynx and neck, ultrasound-guided fine needle 
aspiration of suspect lymph nodes and chest X-ray. All patients over the age of 18, 
WHO performance status ≤1 and squamous cell carcinoma of the larynx and the 
following clinical stage (TNM-classification, UICC 1997), were considered for this 
study: T2 glottic carcinoma with impaired cord mobility or subglottic extension, T2 
supraglottic carcinoma with invasion of the mucosa of the base of tongue or vallecula 
or invasion of the medial wall of the piriform sinus, T3-4 glottic or supraglottic 
carcinoma and any N-stage but M0. 
Exclusion criteria included prior or concurrent treatment for this tumor, severe stridor 
with impossibility for adequate debulking of airway, impaired renal and/or hepatic 
function (creatinine > upper normal limit, ASAT/ ALAT >1.5 times upper limit), use of 
nefrotoxic or anti-convulsant medication that could not be discontinued and a history 
of malignancy during the previous 5 years (with exception of basal cell carcinoma of 
the skin, carcinoma in situ of the cervix or superficial bladder cancer).
Approval for the study was obtained from the Radboud University Nijmegen Medical 
Centre research Ethics Committee with ratification from each centre before start. 
Written informed consent and completed quality of life questionnaire were obtained 
before randomization.
Sample Size
The target sample size was 344 patients (n= 172 per arm), determined to provide 
80% power to detect a difference of 60 vs. 75% in local control rate at 2 years for AR 
vs. ARCON, respectively, allowing for dropouts and a significance level of .05 
(two-sided log-rank test). Follow-up of 2 years after the last inclusion, was respected 
before data analysis. 
Randomization and masking
Patients fulfilling enrollment criteria were centrally randomized by phone at the IKO 
(Integraal Kankercentrum Oost) trials office. Treatment arm assignments (AR vs. 
ARCON) were stratified for tumor site (glottic vs. supraglottic) and institution. A 
dynamic allocation method was used to avoid imbalance of treatment assignment 
within an institution. Randomization took place after all study investigations and no 
longer than 4 weeks prior to the anticipated start of treatment. Data were unmasked.
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Treatment
A CT-scan in treatment position with immobilization device was used in all the 
patients. The initial radiation planning target volume encompassed the primary tumor 
and the lymph node levels II, III and IV in case of cN0. Level V and VI were included 
in case of cN1-3 and >1.0 cm subglottic extension, respectively.18 The boost planning 
target volume encompassed the primary tumor volume and the macroscopic involved 
lymph nodes. A total dose of 44 Gy in 22 daily fractions of 2 Gy was prescribed 
followed by a boost dose of 24 Gy in twice daily fractions of 2 Gy with a minimum 
interval of 6 hours between the fractions. Dose specification and dose homogeneity 
requirements were according to Report 50 of the ICRU.19 The overall treatment time 
was 36-38 days. Because a decrease in radiation tolerance was observed for 
cartilage and spinal cord in earlier studies with hypoxic sensitization, the total dose to 
the arytenoid cartilage and the spinal cord in the ARCON arm was limited to 64 and 
40 Gy, respectively.20,21
Patients allocated to the ARCON arm received carbogen (98% O2 + 2% CO2, 4 
minutes before and during daily fractions) and oral nicotinamide (60 mg/kg, 1-1.5h 
before each fraction) concurrently with radiotherapy.22,23 During the boost nicotinamide 
was given only before the first fraction of the day. To prevent nausea, domperidone 
(10 mg, thrice-daily dosage) was given. 
Hypoxia marker side study
After informed consent, patients received pimonidazole (Hypoxyprobe-1; Natural 
Pharmacia International, Belmont, MA) intravenously (500 mg/m2) two hours before 
biopsy taking. Biopsies were snap frozen in liquid nitrogen, immunohistochemically 
stained and semi-automatically analyzed as described earlier.24 Of each biopsy, one 
complete section was analyzed to define the hypoxic fraction, i.e. the area positive for 
pimonidazole relative to the total tumor area. Based on previous pimonidazole marker 
studies, a cut-off value of 2.6% was used to dichotomize between well-oxygenized 
and hypoxic tumors.
Monitoring During Treatment and Follow-up Evaluations
Acute radiation toxicities were graded according to an earlier validated list of toxicity 
criteria (online only table 1).13 Any other side effects felt to be related to carbogen or 
nicotinamide and the reason for interruption or discontinuation were recorded as well. 
After resolution of the acute radiation toxicities, follow-up visits took place every 2, 3, 
4 months during the first, second and third year respectively, then every 6 months for 
another 2 years. The larynx was assessed by fiberoptic or indirect laryngoscopy. 
Regional control was assessed by palpation of the neck. On suspicion of nodal 
recurrence an ultrasound with fine needle aspiration cytology was performed. 
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Recurrences were cytologically or pathologically confirmed and documented by 
CT-scan or MRI. Eligibility for salvage neck dissection was assessed by a multidisci-
plinary head and neck oncology team. Severe adverse events were defined as either 
events that are fatal, life-threatening or resulting in permanent disability or any late 
toxicity like deep mucosal necrosis, cartilage necrosis or osteoradionecrosis requiring 
surgery.
Endpoints and Statistics
The primary endpoint of the study was local tumor control. Local control was taken 
as freedom of first recurrence at the primary tumor site. Secondary endpoints were 
regional control, larynx preservation, toxicity, quality of life, disease-free survival 
(DFS) and overall survival (OS). Regional control was defined as freedom of first 
regional recurrence. Disease-free survival was defined as the time to a local or 
regional recurrence, distant metastasis, or death from any cause. Overall survival 
was defined as time to death. For larynx preservation, treatment was considered to 
have failed on the date laryngectomy was performed. 
Statistical analyses were performed using SPSS 16.0.1. Survival estimates were 
obtained using the Kaplan-Meier method and all analyses were based on intent-to-
treat policy. All intervals were calculated from the date of randomization and censored 
after 60 months or at last follow-up. Differences were compared using the log-rank 
test and hazard ratios (HR) and their 95% confidence interval (CI) were obtained 
using the Cox proportional hazards model. Differences in prevalence of worst grade 
acute and late toxicities between both treatment arms were compared using the 
Chi-square test. 
Results
Patient Characteristics and Protocol Compliance
Between April 2001 and February 2008, 345 patients were randomized to either AR 
or ARCON (Figure 1). The median follow-up time was 44 (range 18-103), 55 and 60 
months for the whole group and for patients still alive receiving AR and ARCON, 
respectively. Patient demographics and clinical tumor characteristics were well 
balanced without significant differences between the groups (Table 1). Compliance 
to radiotherapy, carbogen breathing and nicotinamide intake was high.16 Radiotherapy 
was delivered as planned to 173 (99%) AR and 169 (99%) ARCON patients and was 
completed within the specified time of 38 days for 168 (97%) AR and 163 (96%) 
ARCON patients. Full compliance to carbogen breathing, nicotinamide intake and 
the combined treatment (ARCON) was 86%, 80% and 76%, respectively. 
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Tumor Control and Survival
Five-year larynx preservation rates were 84% and 87% for AR and for ARCON (P=.48). 
There was no significant difference in local control rate: 80% and 78% for AR versus 
83% and 79% for ARCON at 2 and 5 years, respectively (HR .94; CI .58–1.52; P=.80; 
figure 2A). The 2- and 5-year regional control rates were significantly better with 
ARCON (88% and 86% for AR versus 95% and 93% for ARCON, respectively (HR .46; 
CI .22-.97; P=.04; figure 2B). No significant differences were found for DFS (HR .75, 
CI .50–1.13, P=.16; figure 2C) and OS (HR 1.03; CI .73–1.46; P=.86; figure 2D). In 
exploratory subgroup analysis we did not find significant differences in 5-year local 
control rate between treatment arms when stratified for T-stage or laryngeal subsite. 
Salvage laryngectomy was attempted in 29 of 35 AR and 21 of 28 ARCON recurrences. 
Salvage neck dissection was attempted in 12 of 21 and 8 of 12 patients treated by AR 
and ARCON, respectively. The ultimate 5-year local and regional control rates, 
including salvage therapy were 94% vs. 92% (P=.60) and 92% vs. 98% (P=.21) for AR 
and ARCON, respectively. 
Figure 1  CONSORT flowchart. 
AR, Accelerated Radiotherapy; ARCON, Accelerated Radiotherapy with Carbogen and Nicotinamide
Randomly assigned  
(n = 345) 
AR alone (n = 174) (n = 171) ARCON  
Received allocated intervention  (n = 174) (n = 170) Received allocated intervention 
Did not receive allocated intervention (n = 0) (n = 1) Did not receive allocated intervention 
(n = 1) incorrect diagnosis 
Survival and tumor endpoints  (n = 174) (n = 170) Survival and tumor endpoints  
Late morbidity endpoints    (n = 173)   (n = 170) Late morbidity endpoints 
Excluded from morbidity analysis (n = 1) (n = 1) Excluded from morbidity analysis 
lost to follow-up (n = 1) (n = 1) incorrect diagnosis 
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Translational side study
Two centers participated in the hypoxia marker study and included 79 patients. The 
hypoxic fraction, as defined by pimonidazole staining, varied from 0-19.4% with a 
median value of 1.5%. There was no ascertainable benefit from ARCON with regard 
to local control, neither in the well-oxgenated tumors, nor in the hypoxic tumors 
(Figure 3A,B). However, regional control in the group with a high hypoxic fraction was 
significantly improved with ARCON compared to AR (100% vs. 55%, P=.01), while no 
difference between the treatment arms was observed in the group with a low hypoxic 
fraction (96% for ARCON vs. 92% for AR, P=.70) (Figure 3C,D). Patients with hypoxic 
Figure 2  Kaplan-Meier curves for local control (A), regional control (B), disease-free 
survival (C) and overall survival (D) comparing accelerated radiotherapy only (AR) or 
accelerated radiotherapy plus carbogen and nicotinamide (ARCON). Log-rank P 
values are shown and number of patients at risk against yearly intervals.
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Figure 3  Local control (A,B), regional control (C,D) and disease-free survival (E,F) 
by oxygenation status of the primary tumor and treatment arm. Log-rank P values are 
shown and number of patients at risk against yearly intervals.
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tumors had a substantially higher five-year DFS in the ARCON arm (86%) compared 
to AR (40%), although the difference did not reach the significance level (P=.08) 
(Figure 3E,F). No DFS benefit from ARCON was observed in patients with well 
oxygenated tumors (80% for ARCON vs. 77% for AR, P=.80). 
Toxicity 
Toxicity data have been described extensively in a recent publication.16 Between both 
treatment arms (AR vs. ARCON) no statistically significant difference was observed 
for incidence of acute skin reactions (moist desquamation: 56% vs. 58%, P=.80), 
acute mucosal reactions (confluent mucositis: 79% vs. 85%, P=.14) and symptoms 
related to acute mucositis (severe pain on swallowing: 53% vs. 58%, P=.37; 
nasogastric tube feeding: 28% vs. 28%, P=.98, narcotic medicines required: 58% vs. 
58%, P=.97). There was a small but statistically significant difference in median 
duration of confluent mucositis in favor of AR (2.0 vs. 3.0 weeks, P=.01). 
Analysis of late radiation morbidity did not reveal significant differences between AR 
and ARCON for skin and subcutaneous tissues (severe teleangiectasia: 8% vs. 8%, 
P=.56; severe subcutaneous fibrosis: 7% vs. 9%, P=.26; severe subcutaneous 
edema, 8% vs. 4%, P=.09) and mucous membranes (mucosal ulceration, 8% vs. 6%, 
P=.36; nasogastric tube feeding, 6% vs. 6%, P=.61), respectively. Twelve patients in 
the AR group and 6 patients in the ARCON group received a tracheostomy for severe 
edema with dyspnea and/or stridor. All patients who developed a cartilage necrosis 
could be managed conservatively. Four of them did receive a tracheostomy (n=1 for 
AR, n=3 for ARCON) and there was no need for laryngectomy. One year after 
diagnosis 9% of the patients with the larynx in situ assigned to AR and 7% of patients 
in the ARCON group could swallow only soft foods or liquids and 3% of patients in 
both groups needed nasogastric tube feeding (P=.88). 
Severe adverse events
One patient (AR) died from a cardiac arrest during treatment. The cause of death was 
unrelated to treatment. Another patient (ARCON) died one day after the end of 
treatment due to a gastric bleeding. He was using diclofenac for abdominal pain. 
Causality with nicotinamide was considered uncertain for this patient. Upper airway 
obstruction during radiotherapy, requiring tracheostomy, occurred in 4 patients 
treated by AR and in 1 patient with ARCON. Furthermore, in the ARCON arm one 
patient developed a renal insufficiency and sepsis and one patient was admitted to 
the hospital with severe bleeding from the tumor. 
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Discussion
The addition of carbogen and nicotinamide to a schedule of accelerated radiotherapy 
produces a significant gain in regional control relative to accelerated radiotherapy 
alone but no benefit in local control in patients with T2-T4 laryngeal cancer. This 
improvement in regional control can be entirely attributed to the patients with hypoxic 
tumors as assessed by pimonidazole staining.
Although there was no improvement in local control with ARCON, the result in the 
experimental arm was consistent with the 80% local control rate at 5 years obtained 
in the preceding phase II ARCON trial.14 Unexpectedly, the local control rate in the 
control arm was higher than the 63-76% and 43-50% local control rates observed for 
T3 and T4 laryngeal cancers treated by hyperfractionated and accelerated regimens 
reported at the time of onset of this study.25,26 A possible explanation might be stage 
migration due to better diagnostic imaging, especially when comparing the results 
of a prospective study with retrospective reports of 15 years ago. In the current study 
no significant differences between T-stages were observed. With conventional 
fractionation schedules local control rates are in the order of 67-80%, 30-77% and 
26-52% for T2, T3 and T4 tumors, respectively, indicating that patients with more 
advanced local disease profit most from accelerated fractionation.27,28,29,30,31 
Because the purpose of this study was to arrive at improved tumor control with no 
increase of late laryngeal toxicity, a dose reduction to 64 Gy for the larynx was 
prescribed for patients in the ARCON arm. This dose reduction was based on a 
decrease in radiation tolerance in the order of 10% observed for cartilage when 
radiotherapy was given in hyperbaric oxygen.20 In the current study a similar effect 
was expected from normobaric carbogen with nicotinamide. This 4 Gy absolute dose 
difference on the larynx is a possible explanation for the lack of additional benefit in 
local tumor control with ARCON as compared to AR alone. Based on clinical data, 
dose-response curves have been constructed for head and neck carcinomas.32 
From these, dose-response gradients (gamma value) have been derived as a 
measure of the steepness of the curve. Typical gamma values for larynx carcinoma 
range from 1.5-2.5. This means that for each percent increment in dose, the probability 
of controlling the tumor will increase by approximately 2 percentage points. Given the 
same local control but with 4 Gy less dose, an enhancement of tumor control 
probability of 10-15% can be derived when carbogen and nicotinamide are combined 
with radiotherapy. Thus, although a dose difference of 4 Gy seems modest, the 
corresponding difference in cure rate is significant. 
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In contrast to the primary tumor, the dose delivered to the lymph node metastases in 
the current study was similar (68 Gy) in both arms. The addition of carbogen and 
nicotinamide did lead to a significant improvement of 8% in regional control rate. This 
finding is consistent with the results of a recent systematic review and meta-analysis 
of hypoxia modification in head and neck cancer in which an absolute risk reduction 
of 8% for loco-regional control was observed.33 
The high rate of local and regional control rates in both treatment arms of the current 
trial and the potential to perform successful salvage surgery in case of recurrence 
explains the lack of benefit in overall survival, similar to what is observed after 
conventional radiotherapy with concurrent cisplatinum in the RTOG 91-11 study.2 
In the current study, long-term swallowing function was similar for AR and ARCON. 
One year after treatment, swallowing was limited to soft foods or liquid in 9% and 7% 
of patients respectively. This is lower than the 23% reported in RTOG 91-11.2 However, 
direct comparison is difficult because of potential bias, e.g. RTOG 91-11 included 
more supraglottic tumors. Furthermore, unlike the current study, planned neck 
dissection was performed in case of cN2a or cN2b disease. Neck dissection after 
chemoradiotherapy has been demonstrated to increase the risk of long-term 
dysphagia and laryngeal dysfunction.34 
Recently published data from this study demonstrate that ARCON results in a high 
level of compliance and a toxicity profile, comparable to what is encountered after 
accelerated radiotherapy alone.16,35 The 8% improvement in regional control and 
excellent larynx preservation rate support the evidence that ARCON can achieve a 
therapeutic gain. Probably, head and neck tumors at other subsites, where the 
laryngeal cartilage is not the dose-limiting organ, e.g. oropharynx, will profit more 
from ARCON, especially those with advanced nodal stage. The recently published 
results from a phase III trial with carbogen and nicotinamide for bladder cancer 
confirm the value of this hypoxia-modifying approach.36 Radiotherapy with carbogen 
and nicotinamide produced a significant improvement in local relapse rate, bladder 
conservation rate and overall survival. The additional costs (carbogen, nicotinamide) 
of ARCON are very low, making it a cost-effective regimen.
The present study demonstrates the importance of a proper patient selection that is 
based on the mode of action of the treatment under investigation, as only patients 
with hypoxic tumors did profit from ARCON therapy and no gain was seen in patients 
with well-oxygenated tumors. This finding strongly supports the notion that 
assessment of the tumor oxygenation status provides a powerful selection tool for 
hypoxia-modifying treatment on an individual patient basis. The inclusion of 
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unselected patient populations may be an important reason for the modest 
improvements generally reported by studies employing hypoxic modification.33,37 
Further translational research linked to this study is currently investigating the 
predictive value of a hypoxia-associated gene signature.
Conclusion
The use of ARCON in stage II-IV laryngeal cancer produced a significant gain in 
regional control rate compared to AR, with similar acute and late toxicity. There was 
no difference in local control between the treatment arms. Translational research 
employing a hypoxia marker assay demonstrates that proper patient selection based 
on tumor biology is the key to the success of this approach. 
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Abstract 
Purpose
We report the acute toxicity profile and compliance from a randomized phase III trial 
comparing accelerated radiotherapy (AR) with accelerated radiotherapy plus 
carbogen and nicotinamide (ARCON) in laryngeal cancer. 
Methods and Materials
From April 2001 to February 2008, 345 patients with cT2-4 squamous cell laryngeal 
cancer were randomized to AR (N=174) and ARCON (N=171). Acute toxicity was 
scored weekly until week 8 and every 2-4 weeks thereafter. Compliance to carbogen 
and nicotinamide was reported. 
Results
Between both treatment arms (AR vs. ARCON) no statistically significant difference 
was observed for incidence of acute skin reactions (moist desquamation: 56% vs. 
58%, p=0.80), acute mucosal reactions (confluent mucositis: 79 vs. 85%, p=0.14) 
and symptoms related to acute mucositis (severe pain on swallowing: 53% vs. 58%, 
p=0.37; nasogastric tube feeding: 28 vs. 28%, p=0.98, narcotic medicines required: 
58% vs. 58%, p=0.97). There was a statistically significant difference in median 
duration of confluent mucositis in favor of AR (2.0 vs 3.0 weeks, p=0.01). There was 
full compliance with carbogen breathing and nicotinamide in 86% and 80% of the 
patients with discontinuation in 6% and 12%, respectively. Adjustment of anti-emesis 
prophylaxis was needed in 42% of patients. 
Conclusion
With exception of a slight increase in median duration of acute confluent mucositis, 
the present data reveal a similar acute toxicity profile between both regimens and a 
good compliance with ARCON for clinical stage T2-4 laryngeal cancers. Treatment 
outcome and late morbidity will determine the real therapeutic benefit. 
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Introduction
In the early 1990s, the landmark trial conducted by the Department of Veterans Affairs 
Laryngeal Cancer Study Group has shown that functional larynx preservation 
strategies based on induction chemotherapy followed by definitive radiotherapy do 
not compromise survival when compared with initial total laryngectomy (1). In the 
subsequent randomized RTOG 91-11 trial, the two years larynx preservation rate in 
patients treated with radiotherapy and concurrent cisplatin (88%) differed significantly 
from patients given induction chemotherapy followed by radiotherapy (75%, p=0.005) 
or conventional fractionated radiotherapy alone (70%, p<0.001) (2). In the same 
period, a single institution study with accelerated radiotherapy and carbogen breathing 
and nicotinamide (ARCON) for stage III-IV laryngeal cancer was conducted. This 
approach yielded a 2-year local control rate of 92% (3). Because this rate was higher 
than any previous report in literature, a phase III trial was initiated to assess the 
magnitude of the therapeutic gain.  
In head and neck cancer, tumor cell repopulation and tumor hypoxia are known 
factors determining radiation response. To counteract the clonogenic repopulation 
during therapy, overall duration of radiotherapy is reduced, generally by delivering 
several fractions a day (accelerated radiotherapy; AR). A way of limiting hypoxia is the 
inhalation of carbogen (98% O2 + 2% CO2) to decrease diffusion-limited hypoxia 
combined with nicotinamide, a vasoactive agent to decrease perfusion-limited 
hypoxia (4,5,6,7,8). The combination of both strategies is applied in ARCON. In a 
murine mammary carcinoma an enhancement ratio of 1.9 was obtained with doses 
close to those used clinically (9). In previous trials with head and neck cancer patients, 
feasibility and tolerability were found acceptable despite elevated radiation reactions 
in rapidly repopulating normal tissues (3,10,11). Confluent mucositis was observed in 
95% of patients, however eventually restoration of the mucosal lining was complete in 
all cases (10). Non-compliance of carbogen breathing in 12% of patients was mainly 
due to discomfort with the breathing procedure, usually related to the respiratory 
stimulation caused by the carbon dioxide component (11). Nausea and vomiting were 
the most frequent side effects of nicotinamide and responsible for discontinuation of 
drug intake in 26% of patients (10). However adjustment of the nicotinamide dose and 
anti-emesis prophylaxis reduced the discontinuation rate to 10% (11). More recently, 
the early results of the phase III trial with carbogen and nicotinamide in locally 
advanced bladder cancer (BCON) were published showing no increase in radia-
tion-induced morbidity in the experimental arm (12).  
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The Dutch multicenter ARCON trial randomized patients with cT2-4 laryngeal cancer 
between accelerated radiotherapy (AR) and accelerated radiotherapy plus carbogen 
and nicotinamide (ARCON). This paper reports on the compliance and toxicity to 
carbogen and nicotinamide and the early normal tissue radiation side-effects.
Material and methods
In- and exclusion criteria
Approval for the study was obtained from the Radboud University Nijmegen Medical 
Centre research Ethics Committee with ratification from each centre before start. 
Eligibility was assessed by a multidisciplinary head and neck oncology team. Patients 
underwent a laryngoscopy under general anesthesia with biopsy taking and histological 
assessment of the primary tumor. Further staging consisted of CT- or MR-imaging of 
the larynx and neck with ultrasound guided fine needle aspiration of suspected 
nodes and chest X-ray. 
All patients over the age of 18, WHO performance status ≤1 and with pathological 
confirmed squamous cell carcinoma of the larynx and the following clinical stage 
(TNM-classification, UICC 1997), were considered: cT2 glottic carcinoma with impaired 
cord mobility or subglottic extension, cT2 supraglottic carcinoma with invasion of the 
mucosa of the base of tongue or vallecula or invasion of the medial wall of the piriform 
sinus, cT3-4 glottic or supraglottic carcinoma and any N-stage but M0. 
Written informed consent and completed quality of life questionnaire was obtained 
before randomization. 
Exclusion criteria included prior or concurrent treatment for this tumor, severe stridor 
with impossibility for adequate debulking of airway, impaired renal and/ or hepatic 
function (creatinine > upper normal limit, ASAT/ ALAT > 1.5 times upper limit), use of 
nefrotoxic or anti-convulsant medication that could not be discontinued for the 
duration of the radiation treatment and a history of malignancy during the previous 5 
years (with exception of basal cell carcinoma of the skin, carcinoma in situ of the 
cervix or superficial bladder cancer). 
Randomization
Patients fulfilling enrollment criteria were centrally randomized by phone at the IKO 
(Integraal Kankercentrum Oost) trials office. Treatment arm assignments (AR vs. 
ARCON) were stratified for tumor site (glottis vs. supraglottic) and institution.
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Treatment
Radiotherapy 
A CT-scan in treatment position and immobilization device was used in the majority 
of the patients. The initial planning target volume (PTV1) contained the primary tumor 
with margins and the lymph node levels II, III and IV in case of cN0. Level V and VI 
were added to the PTV1 in case of cN1-3 and >1.0 cm subglottic extension, 
respectively (13). The boost planning target volume (PTV2) encompassed the primary 
tumor volume and the macroscopic involved lymph nodes. A total dose of 44 Gy in 
22 daily fractions of 2 Gy was prescribed on the PTV1 followed by a boost dose of 24 
Gy in twice daily fractions of 2 Gy with a minimum interval of 6 hours between the 
fractions. Because a decrease in the radiation tolerance was observed for cartilage 
and spinal cord in earlier studies, the total dose to the arytenoid cartilage and the 
spinal cord in the ARCON arm was limited to 64 and 40 Gy, respectively (14,15).  
  
Carbogen
A gas mixture of 98% O2 + 2% CO2 was delivered through a closed breathing system. 
Either an anesthetic face mask with airtight seal or a scuba diving mouthpiece with a 
nasal clip was used (16,17). Carbogen breathing was administered 4 minutes prior 
and during irradiation of the macroscopic tumor locations.  
Nicotinamide
A daily oral dose of 60 mg/kg nicotinamide was given 1-1.5 h before the irradiations 
either as capsules or dissolved in water or lemonade. During the bi-fractionation part 
of treatment, nicotinamide was given only before the first fraction of the day.  To 
prevent nausea, domperidone (10 mg, 3 dd) was given prophylactically, starting on 
the first day of treatment. 
Follow-up and scoring of toxicity and acute adverse events
During the treatment and the two weeks thereafter, patients were evaluated weekly by 
the attending radiation oncologist. Depending on the severity of the acute radiation 
reactions, patients were seen every two to four weeks until healing of the reactions. 
Side-effects related to the skin (erythema, dry and moist desquamation) and the 
mucous membranes (mucositis and related symptoms like pain on swallowing, 
severity of dysphagia and required analgesics) were scored as shown in Table 1. Any 
other side-effects felt to be related to the carbogen/ nicotinamide administration and 
the reason for interruption or discontinuation were recorded as well. During the 
treatment haemoglobin, haematocrit, creatinine and urea level were checked weekly. 
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Table 1  Scores for skin and mucosal reactions.
Acute Reactions Score
Skin 
erythema none 0
slight 1
moderate 2
severe 3
unknown 9
dry desquamation % of irradiated surface
moist desquamation % of irradiated surface
Mucous membrane
mucositis none 0
patchy 1
confluent 2
unknown 9
Symptoms related to acute mucositis
pain on swallowing none 0
slight 1
moderate 2
severe 3
not known 9
severity of dysphagia none 0
some discomfort on swallowing, no disturbance on 
diet  
1
difficulty with diet, soft diet required 2
considerable difficulty on swallowing, fluids only 3
severe difficulty on swallowing 4
nasogastric tube or i.v. feeding 5
not known 9
analgesics required none 0
topical medicine only 1
non-narcotic medicines necessary 2
narcotic medicines required 3
not known 9
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Statistics
Chi-square tests were carried out to evaluate differences in prevalence between the 
groups. Kaplan-Meier estimates were used to analyse the duration of the symptoms. 
Results
Between April 2001 and February 2008, 345 patients with a histological diagnosis of 
squamous cell carcinoma of the larynx were randomized to either AR or ARCON in 7 
university hospitals within the Netherlands and the U.K. One patient (ARCON) was 
excluded from analysis because of policy change after randomization. Demographic 
details are presented in table 2. There are no significant differences between the two 
study arms.
Acute skin and mucosal reactions and related symptoms    
In figure 1 the evolution of severe erythema, dry and moist desquamation of the skin 
over the first 16 weeks of treatment is presented. No statistically significant difference 
was observed for occurence of severe erythema (65% vs. 63%, p=0.70), dry 
desquamation (78% vs. 73%, p=0.31) and moist desquamation (56% vs. 58%, 
p=0.80) with AR and ARCON, respectively. Between the groups, there was no 
difference in median duration of dry desquamation (AR vs. ARCON: 3.0 vs. 3.0 
weeks; p=0.78) or moist desquamation (AR vs. ARCON: 1.5 vs. 2.0 weeks; p=0.59). 
Peak incidence of skin reactions in both study arms was seen in the first week after 
the end of radiotherapy (week 7). 
Figure 2 shows the incidence over time of confluent mucositis and related symptoms 
like severe pain on swallowing, nasogastric tube feeding and narcotic medicines 
required. With a peak incidence in the first week after the end of radiotherapy, no 
statistically significant difference was observed between AR and ARCON in 
occurrence of confluent mucositis (79 vs. 85%, p=0.14), severe pain on swallowing 
(53% vs. 58%, p=0.37), nasogastric tube feeding (28 vs. 28%, p=0.98) or narcotic 
medicines required (58% vs. 58%, p=0.97). There was a statistically significant 
difference in median duration of confluent mucositis in favor of AR (2.0 vs. 3.0 weeks, 
p=0.03). At 8 weeks after treatment, healing of patchy and confluent mucositis was 
complete in 87% and 84% (p=0.39) of the patients in the AR group and the ARCON 
group. At this time point tube feeding and narcotics were still required in 6 vs. 5% 
(p=0.85) and 9 vs. 8% (p=0.90) of the AR and ARCON patients, respectively. 
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Table 2  Characteristics of patients, grouped by treatment regimen received.
Characteristics Patients 
(N)
AR 
(N= 174)
ARCON 
(N= 170)
Age (years)
Median 60 61
Range 38-88 41-84
Sex no (%)
male 136 (78%) 141 (83%)
female 38 (22%) 29 (17%)
Site of the primary tumor (%)
Supraglottic 100 (57%) 96 (56%)
Glottic 74 (43%) 74 (44%)
T-stage (%)
T2 67 (38%) 55 (32%)
T3 80 (46%) 95 (56%)
T4 27 (16%) 20 (12%)
N-stage (%)
N0 117 (67%) 116 (68%)
N1 20 (12%) 22 (13%)
N2a 4 (2%) 7 (4%)
N2b 10 (6%) 5 (3%)
N2c 23 (13%) 20 (12%)
N3 0 (0%) 0 (0%)
Participating Institutions 
Radboud University Nijmegen Medical Centre, 
Nijmegen
151 75 76
University Medical Center Utrecht, Utrecht 77 38 39
VU University Medical Center, Amsterdam 40 21 19
University Medical Center Groningen, Groningen 28 15 13
Maastricht University Medical Centre, Maastricht 28 15 13
Leiden University Medical Center, Leiden 17 8 9
Mount Vernon Hospital, Northwood, UK 3 2 1
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Figure 1  Evolution of occurrence of severe erythema (a), dry (b) and moist (c) des- 
quamation with accelerated radiotherapy alone (solid line) or with ARCON (dotted line).
a
b
c
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Figure 2  Evolution of confluent mucositis (a) and related symptoms like severe pain 
on swallowing (b), nasogastric tube/intravenous feeding (c) and need of narcotic 
medicines (d) with accelerated radiotherapy alone (solid line) or ARCON (dotted line).
a
b
c
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Compliance to radiotherapy 
Radiotherapy was delivered as planned to 173 (99%) AR and 169 (99%) ARCON 
patients and was completed within the specified time of 38 days for 168 (97%) AR and 
163 (96%) ARCON patients. Patients with a longer overall treatment time had a mean 
delay of 3 days (range 1-7) and 2 days (range 1-5) for AR and ARCON, respectively. 
One patient (AR) died from a cardiac arrest during treatment. The cause of death was 
unrelated to treatment. Another patient (ARCON), with full compliance to carbogen 
breathing and nicotinamide intake, died one day after the end of treatment due to a 
gastric bleeding. Shortly before he started diclofenac, known to cause gastric 
irritation, for abdominal pain. Causality with nicotinamide was considered uncertain 
for this patient. Upper airway obstruction during radiotherapy, requiring tracheostomy, 
occurred in 4 patients treated by AR and in 1 patient with ARCON. In the experimental 
arm one patient developed a renal insufficiency and sepsis and one patient was 
admitted to the hospital for severe blood spitting based on a tumoral bleeding.    
Compliance and acute toxicity to nicotinamide and carbogen 
The compliance to carbogen breathing was high (N=147/170; 86%) with a temporary 
interruption for a mean period of 2 days (range 1-4) in 12 patients (7%) and discontin-
uation in 11 patients (6%). The main reasons for discontinuation were discomfort with 
the breathing procedure (N=8), cardio-pulmonary co-morbidity (N=2) and stridor 
(N=1).  
Figure 2  Continued.
d
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The majority of the patients fully complied with nicotinamide intake on all days 
radiotherapy was given (N=136/170; 80.0%). There was a temporary interruption in 14 
patients (8%) for a mean period of 3 days (range 1-20) and discontinuation in 20 
patients (12%). The main reasons for nicotinamide discontinuation were nausea and 
vomiting despite domperidon use (N=7), combined discontinuation with carbogen 
breathing (N=7), renal function disturbances (N=2), allergic reaction (N=1) and other 
reasons (N=3). Domperidon dose adjustment and/ or supplementary anti-emetics 
were needed in 72 patients (42%).  
Discussion
The results of this randomized trial, comparing accelerated radiotherapy alone with 
accelerated radiotherapy in combination with carbogen and nicotinamide, reveal a 
good compliance with ARCON and an almost identical acute toxicity profile compared 
to AR for clinical stage T2-4 laryngeal cancers.
Although previous phase I en II head and neck clinical trials do suggest an 
enhancement of acute reactions on normal tissues by a hypoxia reducing regimen, 
early skin and mucosal reactions seem to be equally toxic. A likely explanation for this 
observation is the lower boost dose (64 vs. 68 Gy) given to patients treated with 
ARCON in the current study. This dose reduction was based on a decrease in 
radiation tolerance in the order of 10% observed for cartilage when radiotherapy was 
given in hyperbaric oxygen (14). The purpose was to arrive at equal late laryngeal 
toxicity in both study arms. The equal acute mucosal toxicity can be the result of this 
dose difference as well. 
In contrast to observations in mouse skin in which enhancement ratios of 1.2 to 1.36 
were estimated for early skin reactions, no difference in occurrence and median 
duration of severe erythema, dry or moist desquamation was observed between 
both arms (18,19). In a previous study with accelerated radiotherapy alone, 50% of 
patients develop a moist desquamation (20). When carbogen and nicotinamide are 
added, there is a further increase in the range of 57-65% for a median duration of 2 
weeks (3,10,11). In the current study, no differences between AR and ARCON are 
observed, however results (56% and 58% for AR and ARCON) still fit within the range 
of previous data.
The early reacting tissue of greater clinical relevance remains the mucosal membrane. 
Acceleration alone up to the same dose causes confluent mucositis in up to 90% of 
laryngeal cancer patients with complete healing within 6 weeks after completion in all 
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18 cases (20). Combined with ARCON, confluent mucositis occurred in 91-97% and 
lasted for a median duration of 6 weeks with a of range 1-16 weeks (3,10,11). The 
further enhancement of the mucosal reactions by ARCON was especially reflected by 
a delayed recovery with prolonged healing. Strikingly, this confluent mucositis rate 
was less pronounced in the current trial and although a statistical significant increase 
in median duration is observed, a confluent mucositis period of only 3 weeks (range 
0-20 weeks) is still half of that observed in previous trials.    
    
Given the mild toxicity profile of the current study compared with our previous studies 
and the large number of patients enrolled from Nijmegen (N=144), a subgroup 
analysis was performed (3,10,11). A significantly higher occurrence of confluent 
mucositis (AR & ARCON: 92% & 93% vs. 71% & 79%, p<0.01) and median duration 
of confluent mucositis (AR & ARCON: 3.0 & 5.0 weeks vs. 2.0 & 2.0 weeks, p<0.01) 
was observed for patients treated in Nijmegen compared to the other centers. These 
interesting findings suggest that, despite the fact that the same toxicity scale with 
objective criteria is used, there can be significant inter-observer and inter-institutional 
variations in toxicity scoring. It is of importance to be aware of this phenomenon when 
interpreting data from multicenter studies. This is probably of even greater relevance 
for late toxicity as there is general suspicion that there is underestimation of the incidence 
and severity of late sequelae, especially in combined modality (chemoradiation) trials 
(21). 
Severe pain due to mucositis and associated supportive care like (naso)gastric tube 
feeding did not differ significantly between the two treatment arms. Although the use 
of opioids and tube feeding are subjective parameters and potentially dependent on 
institution protocols, the 28% rate of tube feeding for the whole group is in line with 
the 25-34% observed in the earlier studies (3,10,11).  
The compliance rate for carbogen breathing was 86% and is in the range of the 
Bladder ARCON trial (85%) recently published by Hoskin et al. (12). The rationale for 
use of gases that include a small fraction of carbon dioxide added to oxygen is an 
increase in respiratory drive and better blood perfusion due to the carbon-dioxide 
induced vasodilatation (22,23,24). The net result of carbogen breathing is a significant 
increase in tumor oxygenation as was demonstrated earlier by measurements in 
tumor bearing mice and in head-and neck cancer patients (6,7,8,22). Micro-electrode 
measurements of tissue pO2 consistently indicated improved tumor oxygenation with 
carbon dioxide fractions between 1% and 5% with no significant differences between 
the fractions (22). Subsequently, a gas mixture of 98% O2 and 2% CO2 was chosen 
for the current trial. This resulted in a discontinuation rate of only 6% of patients and 
is better than the previous reported data of 12% and 16% with carbon dioxide 
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concentrations of 5% (3,11). The main reason for discontinuation was discomfort with 
the breathing procedure. 
With 80% of patients receiving 60 mg/kg nicotinamide intake on all days radiotherapy 
was given and discontinuation in only 12% of patients, compliance can be regarded 
as good. Dose adjustments of domperidon and/ or supplementary use of anti-emetics 
were needed in 42% of patients. The potential digestive side-effects may be caused 
by a reduction in peristalsis due to the interaction of nicotinamide with the gastroin-
testinal smooth muscle in a dose-dependent matter (25). Comparative-dose studies 
of mice and humans led to the calculation that, for the radiosensitising effect in 
humans, a nicotinamide plasma concentration of 700 µmol/L was required, which is 
obtained with an oral dose of 80 mg/kg (26,27). However, daily administration of this 
dose during 5 to 7 weeks resulted in discontinuation of nicotinamide intake in over 
25% of patients (10,11,28). Subsequent laser Doppler-flow measurements in patients 
still demonstrated a significant increase in blood flow during inhalation of carbogen 
with nicotinamide doses of 80 mg/kg and 40 mg/kg compared to carbogen alone 
(29). With a reduction in dose to 60 mg/kg and domperidone as antiemetic 
prophylaxis, the rate of discontinuation was significantly improved and in the range of 
the current results (3,11,30). In the bladder BCON trial, only 59% of patients fully 
complied despite anti-emetic prophylaxis and a further 9% completed the treatment 
when the dose was reduced to 40 mg/kg (12). This inferior compliance compared to 
the current trial can probably be explained by the concomitant partial abdomen 
irradiation. 
Conclusion
The result of this phase III randomized trial reveals a similar acute toxicity profile and 
a good compliance with ARCON compared to AR for clinical stage T2-4 laryngeal 
cancers. Although analysis of late toxicity is still ongoing, the current observations 
provide a convenient base for determining the real therapeutic benefit of ARCON.
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Abstract 
Purpose
Anemia is associated with poor tumor control. It was previously observed that 
accelerated radiotherapy combined with carbogen breathing and nicotinamide 
(ARCON) can correct this adverse outcome in patients with head and neck cancer. 
The purpose of this study was to validate this observation based on data from a 
randomized trial. 
Experimental design
Of 345 patients with cT2-4 laryngeal cancer, 174 were randomly assigned to 
accelerated radiotherapy (AR) and 171 to ARCON. Hemoglobin (Hb)-levels, measured 
before treatment, were defined as low when <7.5 mmol/L for women and <8.5 mmol/L 
for men. The hypoxia marker pimonidazole was used to assess the oxygenation status 
in tumor biopsies. Data were analyzed two years after inclusion of the last patient. 
Results 
Pre-treatment Hb-levels were available and below normal in 27/173 (16%) AR and 
27/167 (16%) ARCON patients. In patients with normal pre-treatment Hb-levels 
treatment with ARCON had no significant effect on 5-year loco-regional control (LRC, 
79% vs 75%, P=0.44) and disease-free survival (DFS, 75% vs 70%, P=0.46) compared 
to AR. However, in patients with low pre-treatment Hb-levels ARCON significantly 
improved 5-year LRC (79% vs 53%, P=0.03) and DFS (68% vs 45%, P=0.04). In 
multivariate analysis including other prognostic factors, pre-treatment Hb remained 
prognostic for LRC and DFS in the AR treatment arm. No correlation between 
pre-treatment Hb-levels and pimonidazole uptake was observed. 
Conclusion
Results from the randomized phase 3 trial support previous observations that ARCON 
has the potential to correct the poor outcome of anemic cancer patients.
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Introduction
Up to 40% of patients with solid tumors undergoing radiotherapy are anemic at 
presentation (1). A wealth of data indicate that low pre-treatment hemoglobin (Hb) 
levels are a strong prognostic indicator of poor disease control and survival (2,3,4). 
To overcome the adverse impact of low pre-treatment Hb-levels, correction strategies 
have been applied such as administering erythropoietin and packed cell transfusions. 
However, randomized trials failed to demonstrate the effectiveness of these 
approaches in patients with head and neck or breast cancer, and erythropoietin was 
even counterproductive in some studies (3,5,6,7). 
Disappearance of the adverse impact of anemia was observed in a non-randomized 
phase II trial when accelerated radiotherapy was combined with carbogen breathing 
and nicotinamide (ARCON) (8). This strategy counteracts tumor cell repopulation and 
hypoxic radioresistance (9). Carbogen breathing (98% O2 + 2% CO2) is used to 
decrease diffusion-limited hypoxia while nicotinamide, a vasoactive agent, is added 
to limit hypoxia caused by intermittent reduction of blood flow (9). The same regimen 
has subsequently been studied in a randomized phase III trial, comparing accelerated 
radiotherapy alone (AR) or combined with carbogen and nicotinamide (ARCON) for 
locally advanced laryngeal cancers. Although local control is not improved, it was 
demonstrated that ARCON results in a benefit of 8% in regional control and excellent 
larynx preservation rates without increase of toxicity (10,11). Translational research 
employing the hypoxia marker pimonidazole, demonstrated that proper patient 
selection based on tumor biology is the key to the success of this approach.
Based on the results of the preceding phase II study the hypothesis was generated 
that ARCON can abolish the adverse impact of anemia (8). The purpose of the current 
study is to find support for this observation in the data from the randomized phase III 
study. This paper reports on the impact of ARCON on the prognosis of a cohort of 
larynx cancer patients presenting with pre-treatment anemia.
  
Material and methods
Study Design and Eligibility
This was an open-label, randomized phase III trial comparing AR with ARCON in 
patients with cT2-4 laryngeal cancer. The trial (ClinicalTrials.gov NCT00147732) was 
conducted under the auspices of the Dutch Head and Neck Cancer Group in 7 
centers in the Netherlands and the UK (Table S1). Eligibility criteria are provided in the 
supplementary Table S2.
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Approval for the study was obtained from the Radboud University Nijmegen Medical 
Centre Research Ethics Committee with ratification from each center. Written informed 
consent was obtained before randomization.
Randomization
Patients were centrally randomized by phone at the IKO (Integraal Kankercentrum 
Oost) trials office. Treatment arm assignments (AR vs ARCON) were stratified for 
tumor site (glottic vs supraglottic) and institution. A dynamic allocation method was 
used to avoid imbalance of treatment assignment within an institution. Randomization 
took place after all study investigations and no longer than 4 weeks prior to the 
anticipated start of treatment.
Procedure
A radiation dose of 44 Gy in 22 daily fractions of 2 Gy was prescribed to the primary 
tumor and neck nodes followed by a boost dose of 24 Gy in twice daily fractions of 2 
Gy to the primary tumor and involved lymph nodes. Because a decrease in the 
radiation tolerance was observed for cartilage and spinal cord in earlier studies with 
hypoxic sensitization, the total dose to the arytenoid cartilage and the spinal cord in 
the ARCON arm was limited to 64 and 40 Gy, respectively (12,13). 
Patients allocated to the ARCON arm received carbogen (98% O2 + 2% CO2, 4 minutes 
before and during radiotherapy) and nicotinamide (60 mg/kg, 1-1.5 hours before 
fractions) concurrently with radiotherapy. Details of the procedure are described 
previously (10,11).
All patients participating in this study were treated in academic hospitals with 
accreditation in head and neck oncology by the Dutch Cooperative Head and Neck 
Oncology Group and institution-wide quality assurance programs.
Hypoxia marker analysis
After additional informed consent, patients received pimonidazole (Hypoxyprobe-1; 
Natural Pharmacia International, Belmont, MA) intravenously (500 mg/m2) two hours 
before biopsy taking. Biopsies were snap frozen in liquid nitrogen, immunohisto-
chemically stained and semi-automatically analyzed (14). Of each biopsy, one 
complete section was analyzed for the hypoxic fraction, i.e. the tumor area positive 
for pimonidazole relative to the total tumor area.
Monitoring During Treatment and Follow-up Evaluations
Before and weekly during treatment hemoglobin, hematocrit, creatinine and urea 
levels were obtained. Normal Hb-levels were defined as: 7.5-10 mmol/L for women 
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and 8.5-11 mmol/L for men (women: 12-16 g/dl; men: 13.6-17.7 g/dl). Follow-up visits 
took place every 2, 3, 4 months during the first, second and third year respectively, 
then every 6 months for another 2 years. The larynx was assessed by fiberoptic or 
indirect laryngoscopy. Regional control was assessed by palpation of the neck. 
When tumor recurrence was suspected, imaging (CT-scan or MRI) was performed to 
document the extent of the disease and biopsies were taken for pathological 
confirmation. 
Endpoints and Statistics
Survival endpoints used were loco-regional control (LRC), metastasis-free survival 
(MFS), disease-free survival (DFS) and overall survival (OS) at 5 years from 
randomization. All intervals were calculated from the date of randomization and 
censored after 60 months or at last follow-up. LRC was defined as freedom of first 
recurrence at the primary tumor site and complete and persistent disappearance of 
the pathological lymph nodes after radiotherapy, not including salvage procedures. 
MFS was defined as the time from randomization to distant metastasis. DFS was 
defined as the time to local or regional recurrence, or distant metastasis. OS was 
defined as time to death. 
The primary endpoint of the randomized trial was local control. In the AR arm a local 
control rate of 60% at 2 years after completion of radiotherapy was expected. An 
improvement by 15%, resulting in a local control rate of 75% at 2 years, was assumed 
for the ARCON arm. In order to detect this difference of 15% with a significance level 
of 0.05 and a power of 0.80 (two-sided log-rank test), 156 patients were required in 
each treatment group. To account for a drop out percentage of 10%, an extra 16 
patients were added for each group. 
Statistical analyses were performed using SPSS 19.0.0. Mann-Whitney U and 
Chi-square tests were used at a two-sided significance level of 0.05. Endpoints were 
evaluated by the Kaplan-Meier method based on intent-to-treat policy and compared 
with log-rank testing. A multivariate Cox proportional hazards analysis, with stepwise 
backward elimination of variables at P>0.1, was used for both patient groups and 
included N-classification (N+ vs N0), performance status (0 vs 1) and treatment arm 
(ARCON vs AR). An interaction between treatment arm and pre-treatment Hb-level 
was assessed using Cox regression. 
Role of the funding source
The study sponsors had no role in the study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access 
to all of the data and the final responsibility to submit for publication. 
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Results
Patient Characteristics and Protocol Compliance
Between April 2001 and February 2008, 345 patients were randomized to either AR 
(n=174) or ARCON (n=171) (Figure 1). The median follow-up time was 44 (range 
18-103), 55 and 60 months for the whole group and for patients still alive receiving AR 
and ARCON, respectively. Patient demographics and clinical tumor characteristics 
were well balanced without significant differences within the whole study population 
and the group of patients presenting with anemia (Table 1). Patients presenting with 
anemia were older (P=0.01), had a poorer performance status (P<0.01), more N2 
stages (P<0.01) and higher stage grouping (P=0.02) compared to the whole group 
of patients. Compliance to radiotherapy, carbogen breathing and nicotinamide intake 
was high and comparable between both groups. Detailed information is listed in the 
supplementary Table S3.
Figure 1  CONSORT diagram.
Randomly assigned (N=345) 
Allocated to AR (N=174) Allocated to ARCON (N=171)
Received allocated intervention (N=174) Received allocated intervention (N=170)
Did not receive allocated intervention (N=0) Did not receive allocated intervention (N=1)
incorrect diagnosis (N=1)
  
Analyzed (N=173) Analyzed (N=167) 
Excluded from hemoglobin subgroup analysis (N=1) Excluded from hemoglobin subgroup analysis (N=3)
no data available (N=1) no data available (N=3)
AR: Accelerated Radiotherapy
ARCON: Accelerated Radiotherapy with Carbogen and Nicotinamide  
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Table 1   Demographics and clinical characteristics for all patients (N=345) and 
patients presenting with anemia (N=54).
All patients Anemic patients
Characteristics AR ARCON P AR ARCON P  
 (N=174) (N=171)  (N=27) (N=27)  
Age - yr 0.56a 0.48a
Median 60 61 63 64
Range 38-88 41-84 48-76 43-80
Sex - no. (%) 0.16b 0.10b
Male 136 (78) 142 (83) 22 (81) 26 (96)
Female 38 (22) 29 (17) 5 (19) 1 (4)
Performance status - no. (%) 0.54b 0.43b
0 140 (80) 137 (81) 16 (59) 17 (63)
1 34 (20) 34 (19) 11 (41) 10 (37)
Site of the primary tumor - no. (%) 0.49b 0.50b
Supraglottic 100 (57) 97 (56) 17 (63) 17 (63) 
Glottic 74 (43) 74 (44) 10 (37) 10 (37)
AJCC stage groupings - no. (%) 0.35b 0.07b
Stage II 53 (31) 46 (27) 9 (33) 4 (15)
Stage III 65 (37) 77 (45) 4 (15) 11 (41)
Stage IV 56 (32) 48 (28) 14 (52) 12 (44)
T-stage - no. (%) 0.20b 0.12b
T2 67 (38) 55 (32) 13 (48) 6 (22)
T3 80 (46) 95 (56) 11 (41) 15 (56)
T4 27 (16) 21 (12) 3 (11) 6 (22)
N-stage - no. (%) 0.58b 0.29b
N0 117 (67) 116 (68) 15 (56) 17 (63)
N1 20 (12) 23 (13) 0 (0) 2 (7)
N2a 4 (2) 7 (4) 2 (7) 3 (11)
N2b 10 (6) 5 (3) 2 (7) 0 (0)
N2c 23 (13) 20 (12) 8 (30) 5 (19)
N3 0 (0) 0 (0) 0 (0) 0 (0)
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Hemoglobin levels 
Pre-treatment Hb-levels were available and below normal in 27/173 (16%) AR and 
27/167 (16%) ARCON patients (Table 1). Four of them (AR n=3; ARCON n=1) received 
a transfusion, given as two units of packed red blood cells. A correlation was observed 
between low Hb at presentation and lower performance status (P<0.01), and a trend 
was observed between low Hb and higher N-status (P=0.06). 
Loco-regional control and survival
In patients with normal pre-treatment Hb-levels treatment with ARCON had no 
significant effect on 5-year LRC (79% vs 75%, P=0.44) and DFS (75% vs 70%, 
P=0.46) compared to AR. However, in patients with low pre-treatment Hb-levels 
ARCON treatment significantly improved 5-year LRC (79% vs 53%, P=0.03) and DFS 
(68% vs 45%, P=0.04) (Figure 2A, 2B). No significant benefit of ARCON was observed 
for MFS (normal Hb: ARCON vs AR: 91% vs 89%, P=0.56; low Hb: ARCON vs AR 87% 
vs 69%, P=0.10; Figure 3A). Patients presenting with low Hb-levels had a worse 
5-year OS regardless of the treatment regimen (normal Hb: ARCON vs AR: 65% vs 
65%, P=0.93; low Hb: ARCON vs AR 46% vs 28%, P=0.97; Figure 3B). 
Table 1  Continued.
All patients Anemic patients
Characteristics AR ARCON P AR ARCON P  
 (N=174) (N=171)  (N=27) (N=27)  
Pre-treatment Hemoglobin - no. (%) 0.49b
Normal 146/173 (84) 140/167 (84) 0/27 (0) 0/27 (0)
Low 27/173 (16) 27/167 (16) 27/27 (100) 27/27 (100)
Male mmol/L
Median 9.2 9.1 8.0 8.1
Range 6.1-14.5 6.1-13.4 6.1-8.4 6.1-8.4
Female mmol/L 
Median 8.4 8.3 7.3 7.2
Range 5.8-11.0 7.2-9.9  5.8-7.4 7.2-7.2  
a Mann-Withney U test
b Chi-Square test
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Prognostic factors for tumor control 
The impact of various common prognostic factors and Hb-levels on LRC, MFS, DFS 
and OS is summarized in Table 2. On multivariate analysis after correction for N-stage 
and Hb-level, ARCON treatment remained an independent prognostic factor for LRC 
(P=0.04) and DFS (P=0.09) in anemic patients only. A significant interaction between 
treatment effect and Hb-level was found for LRC (P=0.02) and DFS (P=0.05).
Hypoxia marker study
Tumor biopsies of 79 patients were available for pimonidazole staining. Characteristics 
were well balanced between patients receiving AR and ARCON (Table 3). However, 
the group of patients participating in the hypoxia marker study differed in some 
aspects from the entire study population: patients involved were more frequently 
female (P<0.01) and presented with higher tumor stage (P<0.01). 
Figure 2  A-B. Loco-regional control (2A) and disease-free survival (2B) for patients 
with low and normal pre-treatment hemoglobin levels, treated by AR or ARCON.
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Table 2   Univariate and multivariate analysis per Hb levels.
Normal Hb (N=286) Low Hb (N=54) Normal Hb (N=286) Low Hb (N=54)
  HR (95% CI) P HR (95% CI) P   HR (95% CI) P HR (95% CI) P
Loco-regional Control Disease-free Survival
Univariate parameter Univariate parameter 
Age >60 vs ≤60 0.94 (0.57-1.55) 0.81 0.47 (0.18-1.22) 0.12 Age >60 vs ≤60 0.90 (0.57-1.43) 0.65 0.55 (0.23-1.30) 0.17
Sex Female vs Male 0.30 (0.12-0.76) 0.01 1.31 (0.30-5.77) 0.72 Sex Female vs Male 0.42 (0.20-0.87) 0.02 1.06 (0.25-4.59) 0.94
Site Supraglottic vs Glottic 0.81 (0.49-1.33) 0.40 1.45 (0.51-4.13) 0.48 Site Supraglottic vs Glottic 1.02 (0.64-1.62) 0.93 1.59 (0.61-4.09) 0.34
T-classification T2 vs T3-4 0.85 (0.52-1.42) 0.54 0.99 (0.37-2.67) 0.98 T-classification T2 vs T3-4 0.93 (0.58-1.50) 0.77 0.92 (0.38-2.22) 0.85
N-classification N+ vs N0 1.85 (1.12-3.06) 0.02 2.91 (1.10-7.68) 0.03 N-classification N+ vs N0 2.20 (1.39-3.48) <0.01 2.98 (1.25-7.12) 0.01
Performance Status 0 vs 1 0.58 (0.25-1.34) 0.20 1.68 (0.65-4.35) 0.29 Performance Status 0 vs 1 0.86 (0.44-1.69) 0.67 1.39 (0.58-3.30) 0.46
Treatment ARCON vs AR 0.82 (0.49-1.35) 0.43 0.31 (0.11-0.89) 0.03 Treatment ARCON vs AR 0.84 (0.53-1.33) 0.45 0.44 (0.18-1.05) 0.06
Multivariate analysis Multivariate analysis
N-classification N+ vs N0 1.86 (1.12-3.06) 0.02 3.17 (1.19-8.42) 0.02 N-classification N+ vs N0 2.20 (1.39-3.48) <0.01 3.56 (1.49-8.50) <0.01
Performance Status 0 vs 1 0.60 (0.26-1.39) 0.23 1.91 (0.72-5.06) 0.19 Performance Status 0 vs 1 0.91 (0.46-1.77) 0.77 1.44 (0.61-3.42) 0.41
Treatment ARCON vs AR 0.80 (0.48-1.33) 0.39 0.33 (0.11-0.93) 0.04 Treatment ARCON vs AR 0.82 (0.51-1.30) 0.40 0.47 (0.20-1.13) 0.09
  Metastasis-Free Survival   Overall Survival
Univariate parameter Univariate parameter 
Age >60 vs ≤60 0.63 (0.28-1.44) 0.28 0.61 (0.17-2.16) 0.44 Age >60 vs ≤60 1.54 (1.03-2.30) 0.04 1.08 (0.48-2.43) 0.86
Sex Female vs Male 0.70 (0.24-2.04) 0.51 1.07 (0.14-8.50) 0.95 Sex Female vs Male 0.74 (0.44-1.24) 0.25 1.84 (0.54-6.20) 0.33
Site Supraglottic vs Glottic 1.95 (0.81-4.71) 0.14 1.26 (0.32-4.85) 0.74 Site Supraglottic vs Glottic 1.18 (0.79-1.76) 0.41 0.82 (0.38-1.76) 0.61
T-classification T2 vs T3-4 1.47 (0.61-3.54) 0.40 0.86 (0.24-3.07) 0.82 T-classification T2 vs T3-4 1.29 (0.85-1.97) 0.23 1.24 (0.57-2.68) 0.59
N-classification N+ vs N0 4.80 (2.06-11.22) <0.01 2.82 (0.79-10.06) 0.11 N-classification N+ vs N0 1.66 (1.12-2.48) 0.01 1.81 (0.87-3.77) 0.11
Performance Status 0 vs 1 1.51 (0.56-4.05) 0.41 1.78 (0.51-6.14) 0.37 Performance Status 0 vs 1 1.99 (1.25-3.16) <0.01 1.44 (0.67-3.09) 0.35
Treatment ARCON vs AR 0.78 (0.34-1.76) 0.55 0.35 (0.09-1.33) 0.12 Treatment ARCON vs AR 1.02 (.69-1.51) 0.93 0.99 (0.47-2.05) 0.97
Multivariate analysis Multivariate analysis
N-classification N+ vs N0 4.80 (2.06-11.22) <0.01 3.31 (0.95-11.5) 0.06 N-classification N+ vs N0 1.17 (1.03-1.33) 0.02 1.22 (0.99-1.50) 0.06
Performance Status 0 vs 1 1.78 (0.66-4.78) 0.26 1.63 (0.49-5.39) 0.43 Performance Status 0 vs 1 2.04 (1.29-3.25) <0.01 1.56 (0.72-3.37) 0.26
Treatment ARCON vs AR 0.74 (0.33-1.66) 0.46 0.41 (0.11-1.55) 0.19 Treatment ARCON vs AR 1.05 (0.70-1.55) 0.83 1.18 (0.56-2.47) 0.67
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Table 2   Univariate and multivariate analysis per Hb levels.
Normal Hb (N=286) Low Hb (N=54) Normal Hb (N=286) Low Hb (N=54)
  HR (95% CI) P HR (95% CI) P   HR (95% CI) P HR (95% CI) P
Loco-regional Control Disease-free Survival
Univariate parameter Univariate parameter 
Age >60 vs ≤60 0.94 (0.57-1.55) 0.81 0.47 (0.18-1.22) 0.12 Age >60 vs ≤60 0.90 (0.57-1.43) 0.65 0.55 (0.23-1.30) 0.17
Sex Female vs Male 0.30 (0.12-0.76) 0.01 1.31 (0.30-5.77) 0.72 Sex Female vs Male 0.42 (0.20-0.87) 0.02 1.06 (0.25-4.59) 0.94
Site Supraglottic vs Glottic 0.81 (0.49-1.33) 0.40 1.45 (0.51-4.13) 0.48 Site Supraglottic vs Glottic 1.02 (0.64-1.62) 0.93 1.59 (0.61-4.09) 0.34
T-classification T2 vs T3-4 0.85 (0.52-1.42) 0.54 0.99 (0.37-2.67) 0.98 T-classification T2 vs T3-4 0.93 (0.58-1.50) 0.77 0.92 (0.38-2.22) 0.85
N-classification N+ vs N0 1.85 (1.12-3.06) 0.02 2.91 (1.10-7.68) 0.03 N-classification N+ vs N0 2.20 (1.39-3.48) <0.01 2.98 (1.25-7.12) 0.01
Performance Status 0 vs 1 0.58 (0.25-1.34) 0.20 1.68 (0.65-4.35) 0.29 Performance Status 0 vs 1 0.86 (0.44-1.69) 0.67 1.39 (0.58-3.30) 0.46
Treatment ARCON vs AR 0.82 (0.49-1.35) 0.43 0.31 (0.11-0.89) 0.03 Treatment ARCON vs AR 0.84 (0.53-1.33) 0.45 0.44 (0.18-1.05) 0.06
Multivariate analysis Multivariate analysis
N-classification N+ vs N0 1.86 (1.12-3.06) 0.02 3.17 (1.19-8.42) 0.02 N-classification N+ vs N0 2.20 (1.39-3.48) <0.01 3.56 (1.49-8.50) <0.01
Performance Status 0 vs 1 0.60 (0.26-1.39) 0.23 1.91 (0.72-5.06) 0.19 Performance Status 0 vs 1 0.91 (0.46-1.77) 0.77 1.44 (0.61-3.42) 0.41
Treatment ARCON vs AR 0.80 (0.48-1.33) 0.39 0.33 (0.11-0.93) 0.04 Treatment ARCON vs AR 0.82 (0.51-1.30) 0.40 0.47 (0.20-1.13) 0.09
  Metastasis-Free Survival   Overall Survival
Univariate parameter Univariate parameter 
Age >60 vs ≤60 0.63 (0.28-1.44) 0.28 0.61 (0.17-2.16) 0.44 Age >60 vs ≤60 1.54 (1.03-2.30) 0.04 1.08 (0.48-2.43) 0.86
Sex Female vs Male 0.70 (0.24-2.04) 0.51 1.07 (0.14-8.50) 0.95 Sex Female vs Male 0.74 (0.44-1.24) 0.25 1.84 (0.54-6.20) 0.33
Site Supraglottic vs Glottic 1.95 (0.81-4.71) 0.14 1.26 (0.32-4.85) 0.74 Site Supraglottic vs Glottic 1.18 (0.79-1.76) 0.41 0.82 (0.38-1.76) 0.61
T-classification T2 vs T3-4 1.47 (0.61-3.54) 0.40 0.86 (0.24-3.07) 0.82 T-classification T2 vs T3-4 1.29 (0.85-1.97) 0.23 1.24 (0.57-2.68) 0.59
N-classification N+ vs N0 4.80 (2.06-11.22) <0.01 2.82 (0.79-10.06) 0.11 N-classification N+ vs N0 1.66 (1.12-2.48) 0.01 1.81 (0.87-3.77) 0.11
Performance Status 0 vs 1 1.51 (0.56-4.05) 0.41 1.78 (0.51-6.14) 0.37 Performance Status 0 vs 1 1.99 (1.25-3.16) <0.01 1.44 (0.67-3.09) 0.35
Treatment ARCON vs AR 0.78 (0.34-1.76) 0.55 0.35 (0.09-1.33) 0.12 Treatment ARCON vs AR 1.02 (.69-1.51) 0.93 0.99 (0.47-2.05) 0.97
Multivariate analysis Multivariate analysis
N-classification N+ vs N0 4.80 (2.06-11.22) <0.01 3.31 (0.95-11.5) 0.06 N-classification N+ vs N0 1.17 (1.03-1.33) 0.02 1.22 (0.99-1.50) 0.06
Performance Status 0 vs 1 1.78 (0.66-4.78) 0.26 1.63 (0.49-5.39) 0.43 Performance Status 0 vs 1 2.04 (1.29-3.25) <0.01 1.56 (0.72-3.37) 0.26
Treatment ARCON vs AR 0.74 (0.33-1.66) 0.46 0.41 (0.11-1.55) 0.19 Treatment ARCON vs AR 1.05 (0.70-1.55) 0.83 1.18 (0.56-2.47) 0.67
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The hypoxic fraction, as defined by pimonidazole staining, varied from 0-19.4% with 
a median value of 1.6%. Eleven of the 79 patients had Hb-levels below normal at 
diagnosis. No correlation was observed between pre-treatment Hb-levels and 
hypoxic fraction (P=0.11).
Figure 3  A-B. Metastasis-free survival (3A) and overall survival (3B) for patients with 
low and normal pre-treatment hemoglobin levels, treated by AR or ARCON.
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Table 3   Demographics and clinical characteristics of patients (N=79) 
participating in the hypoxia marker study.
Characteristics AR ARCON P
 (N=38) (N=41)  
Age - yr 0.41a
Median 61 61
Range 38-81 46-83
Sex - no. (%) 0.99b
Male 26 (68) 28 (68)
Female 12 (32) 13 (32)
Performance status - no. (%) 0.71b
0 29 (76) 34 (83)
1 9 (24) 7 (17)
Site of the primary tumor - no. (%) 0.99b
Supraglottic 25 (66) 27 (66)
Glottic 13 (34) 14 (34)
T-stage - no. (%) 0.16b
T2 11 (29) 6 (15)
T3 20 (53) 30 (73)
T4 7 (18) 5 (12)
N-stage - no. (%) 0.24b
N0 17 (45) 20 (49)
N1 10 (26) 5 (12)
N2a 3 (8) 1 (2)
N2b 1 (3) 4 (10)
N2c 7 (18) 11 (27)
N3 0 (0) 0 (0)
Pre-treatment Hemoglobin - no. (%) 0.27b
Normal 31 (82) 37 (90)
Low 7 (18) 4 (10)
Male mmol/L 
Median 9.0 9.1
Range 7.7-10.3 6.8-10.4
Female mmol/L 
Median 7.9 8.2
Range 7.4-9.3 7.5-9.9
a Mann-Withney U test
b Chi-Square test
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Discussion
It has been demonstrated by numerous reports that anemia in patients with cancer of 
the cervix, head and neck, bladder, breast and lung is associated with poor outcome 
(2,3,4). This is also found in the current study for patients with T2-4 laryngeal cancer 
treated with radiotherapy alone. However, this impaired outcome in anemic patients 
is not longer observed when carbogen and nicotinamide are added to radiotherapy, 
supporting the results of a previous phase II ARCON-trial in head and neck cancer (8). 
Attempts have been made to improve outcome of anemic cancer patients using 
erythropoietin or red blood cell transfusions. A Cochrane review based on five 
randomized controlled trials found strong indications that for head and neck cancer 
patients, the addition of erythropoietin to radiotherapy negatively affects patient 
outcome in terms of loco-regional progression free survival and overall survival (7). 
Suggested explanations for the lack of benefit of erythropoietin include presence of 
erythropoietin receptors on the tumor cell membranes stimulating tumor growth, and 
a decrease of tissue oxygenation due to increased viscosity when Hb concentrations 
become too high (15,16,17). Head and neck cancer patients with low Hb-levels treated 
in the DAHANCA 5 (radiotherapy and nimorazole vs radiotherapy and placebo) and 
DAHANCA 7 (conventional radiotherapy vs accelerated radiotherapy) studies were 
sub-randomized to receive red blood cell transfusions prior to and during radiotherapy 
(3). Also with this approach, the increased Hb-level was not able to improve tumor 
control or survival. Stimulation of inflammatory and immunosuppressive pathways 
was proposed as a possible factor involved (18). Randomized trials exploring the role 
of chemotherapy in addition to radiotherapy for patients presenting with anemia are 
lacking. However, prospective and retrospective studies indicate that the poor 
prognosis of patients presenting with anemia cannot be improved by a chemoradio-
therapy approach (19,20).
The “reduced cord radius” model described by Hirst and colleagues could explain 
the success of ARCON in anemic patients (21). The term “tumor cord” describes the 
functional unit of a blood vessel and its dependent tumor cell volume1*. The model 
assumes that the ability of cancer cells to survive at a distance from blood vessels is 
dependent on the local supply and diffusion distance of oxygen and nutrients from 
each vessel. Histological examination of tumors in animals exposed to low oxygen 
tension for several days has shown that the thickness of the tumor cords is less than 
1 *  Although the typical corded structure is histologically recognizable in some tumors and tumor 
types, the cord radius model has a broader application. “Cord radius” is the equivalence of the more 
generally applicable and easier to recognize “distance from blood vessel to necrosis”. However, for 
readability we use the term “tumor cord” here.
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in animals breathing normal air (22). It has been proposed that anemia causes a 
reduced cord radius by the same mechanism. Restoration of Hb-levels by blood 
transfusion in anemic animals produced a markedly increased tumor radiosensitivity 
supposedly by improved oxygenation of tumor cells in the peripheral zones of the 
cords. However, this effect was only transient and was lost within 24 hours (23). Tumor 
cords that are chronically exposed to higher oxygen levels, will adapt and begin to 
proliferate more actively and will once again outgrow their oxygen supply. In contrast, 
daily carbogen breathing immediately followed by radiotherapy will not cause this 
adaptive response because the oxygenation increase is too short and only for the 
duration of the radiation treatment (10-15 min). The status quo of reduced cord radius 
and, consequently, shorter oxygen diffusion distances in combination with higher 
levels of free oxygen in plasma explains how ARCON can exploit adaptive mechanisms 
in anemic patients. Additionally, since the effect of carbogen relies on oxygen 
transportation by the plasma, the reduced blood viscosity and consequential 
increased flow through the tumor microvasculature will further benefit the anemic 
patients. Finally, other compensatory mechanisms such as a shift in the oxygen-he-
moglobin dissociation relationship may contribute as well.
Although the effect of hyperbaric oxygen in patients with head and neck cancer has 
recently been demonstrated in a systematic review and meta-analysis, prospective 
data testing hyperbaric oxygen in relation to anemia are lacking (24). However, a 
retrospective analysis of patients with carcinoma of the uterine cervix treated with 
radiotherapy in hyperbaric oxygen also revealed a marked improvement in local 
tumor control in patients who were severely anemic prior to radiotherapy (25). 
Additional support comes from a preclinical study demonstrating that hyperbaric 
oxygen was successful in overcoming the increased radioresistance associated with 
anemia in mouse mammary adenocarcinomas (26). These observations are of 
interest because several mechanisms of action of ARCON discussed above also 
apply to hyperbaric oxygen.
Another issue is why anemic patients have an inferior outcome compared to 
non-anemic patients in the first place. It is generally assumed that this is primarily a 
consequence of the impaired tumor oxygenation resulting in a more aggressive and 
treatment resistant tumor phenotype (15,27). Indeed, clinical and pre-clinical studies 
do provide evidence for a correlation between Hb-level and tumor hypoxia measured 
by polarographic pO2 electrodes (15,16,28,29). In particular, this association is 
present in severely anemic patients (Hb <11.0 g/dl (< 6.9 mmol/L)) whereas it is 
much weaker in patients with mild anemia or low normal Hb-levels. One study did not 
demonstrate such correlation, but it should be noted that in that study there were 
hardly any patients with severe anemia (30). This was also the case in the current 
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study: in the subgroup of patients, participating in the hypoxia marker side study, no 
correlation was found between tumor hypoxia as measured by pimonidazole binding 
and Hb-level but there was only one patient with a Hb-level below 11.0 g/dl. Only 
79/345 patients took part in this side study. This is mainly due to a late amendment to 
the initial protocol and the limited number of participating centers to the side study. 
On the other hand, we argue that it is not the absolute amount of hypoxia but the 
distribution as function of distance to the vessels that is relevant for the response to 
ARCON.
Tumor hypoxia may be one reason for the poor prognosis of anemic patients but 
most likely not the only one. A typical molecular feature of malignancies is the switch 
in tumor cell metabolism from oxidative to glycolytic pathways (31,32). Anaerobic 
glycolysis provides cells with a growth advantage in the tumor microenvironment and 
promotes metastasis formation. With decreased blood viscosity and increased 
plasma flow in anemic patients there will be greater availability of glucose, fuelling the 
process of malignant progression. This can explain the observation of an association 
between anemia and the trend towards a higher N-stage (P=0.06) in this study. Apart 
from a causative factor, anemia can also be an epiphenomenon of aggressive tumor 
behaviour. Activation of the immune and inflammatory system by the malignant 
disease produces cytokines, including interferons, tumor necrosis factor and 
interleukin-1 (33). These cytokines inhibit erythropoiesis, affect the life span of 
erythrocytes and impair iron metabolism.
Despite reduction of tumor recurrence, no benefit of ARCON was observed on OS in 
anemic patients. The correlation between low Hb-levels and a poorer performance 
status (P<0.01), observed in this study, suggests that associated co-morbidity in 
patients with low Hb-levels at diagnosis may affect survival independent of tumor 
control. Supportive evidence for this comes from the GORTEC 94-01 trial comparing 
radiotherapy alone with concomitant radiochemotherapy in advanced-stage 
oropharynx carcinoma. This study showed that anemia was associated with a higher 
probability of death caused by intercurrent disease (20). In our cohort of patients 
presenting with anemia, approximately 40% exhibit significant co-morbidity. It is 
obvious that the survival impact of co-morbidity cannot be influenced by ARCON or 
any other cancer treatment (34).
In conclusion, the poor prognosis of laryngeal cancer patients with pre-treatment anemia 
is not longer observed when radiotherapy is combined with carbogen breathing and 
nicotinamide. This observation of improved outcome in anemic patients supports an 
earlier proposed hypothesis (8). Reduced oxygen diffusion distances in the tumor 
and improved oxygen transportation by the plasma due to reduced blood viscosity 
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can explain the effectiveness of ARCON in anemic patients. The potential of ARCON 
should be further explored in a large prospective randomized trial with focus on 
patients presenting with anemia. 
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Abstract 
Purpose
Retrospective studies indicate that larger tumour volume is a strong prognostic 
indicator for poor tumour control after (chemo)radiotherapy for laryngeal cancer. The 
impact of tumour volume on the outcome of patients treated within a prospective 
study comparing accelerated radiotherapy (AR) ± carbogen breathing and 
nicotinamide (ARCON) was investigated. 
Methods and Materials
Of 345 patients with cT2-4 laryngeal cancer, pre-treatment CT-scans of 270 patients 
were available for tumour volume calculation. Contouring of the primary tumour and 
involved lymph nodes was reviewed by one experienced head and neck radiation 
oncologist. Kaplan-Meier plots were used for analysis of outcome.
Results
Of 137 AR and 133 ARCON patients, 57 and 80 vs. 56 and 77 patients had glottic and 
supraglottic tumours, respectively. A correlation between primary tumour volume and 
T-stage was observed (Rs=.51, P<.01). In both treatment arms no correlation was 
detected between the primary tumour volume and local control (LC), regional control 
(RC) and metastasis-free survival (MFS). A strong correlation between total nodal 
volume and N-stage was found (Rs=.93, P<.01). Both in the AR and ARCON groups 
total nodal volume was not associated with poorer RC rate. However, based on 
individual lymph node analyses, nodal control was in favour of ARCON, irrespective 
of volume  (P<.01). 
Conclusion
Neither primary tumour volume, nor total nodal volume are prognostic factors for 
patients with cT2-4 laryngeal cancer treated with accelerated radiotherapy ± 
carbogen breathing and nicotinamide. Additional analyses based on individual nodal 
volumes demonstrate an excellent regional control rate and a significant benefit of 
ARCON.
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Introduction
Several retrospective studies demonstrate that the macroscopic primary tumour 
volume, as calculated from pre-treatment CT- or MR scans, can predict local control 
in squamous cell carcinoma arising in different subsites of the head and neck area in 
patients who are treated with definitive (chemo)radiotherapy.1-4 Threshold volumes 
have been identified in naso-, oro-, hypopharyngeal and laryngeal tumours to counsel 
patients regarding the relative likelihood of local tumour control.1,2 The University of 
Florida repeatedly demonstrated that volumes greater than 3.5 cm3 and 6.0 cm3, 
respectively for glottic and supraglottic tumours, are inversely related to local control.5-9 
Studer et al. also demonstrated in a cohort of patients with head and neck cancer 
treated with IMRT that there is a stronger association between primary tumour volume 
and local control than the association between T-stage and local control.2 
Less data are available with respect to the volume of involved lymph nodes and nodal 
control in head and neck cancer. Disease control of involved lymph nodes by 
radiotherapy decreases with increasing maximum lymph node diameter.10-12 Only a 
limited number of reports analysed 3D-CT lymph node volumes and found that total 
nodal volume was a significant prognostic factor for regional control.13-16 
In the Netherlands a randomised trial was performed in patients with advanced 
carcinoma of the larynx comparing accelerated radiotherapy (AR) with accelerated 
radiotherapy with carbogen breathing and nicotinamide (ARCON) for hypoxic 
sensitisation. The inhalation of carbogen (98% oxygen + 2% carbon dioxide) 
decreases diffusion-limited hypoxia and the administration of nicotinamide, a 
vasoactive agent, reduces perfusion-limited hypoxia. It was demonstrated that 
hypoxia modulation by ARCON resulted in an improvement of 8% in regional control 
but there was no effect on local control.17 Interestingly, in both treatment arms, T-stage 
was not prognostic for outcome. The purpose of the current study is to analyse the 
impact of primary tumour volume and nodal volume on prognosis in this large and 
homogeneous cohort of patients.
Patients and methods
Phase III ARCON trial 
This was an open-label, randomised phase III trial comparing AR with ARCON in 
patients with cT2-4 laryngeal cancer. The trial (ClinicalTrials.gov NCT00147732) was 
conducted under the auspices of the Dutch Head and Neck Cancer Group in 7 
centers in the Netherlands and the UK. Eligibility criteria and details of the procedure 
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are described previously.18 Briefly, a radiation dose of 44 Gy in 22 daily fractions of 2 
Gy was prescribed to the primary tumour and neck nodes followed by a boost dose 
of 24 Gy in twice daily fractions of 2 Gy to the primary tumour and involved lymph 
nodes. Treatment of the neck nodes was by radiotherapy alone, no planned neck 
dissections were performed. Because a decrease in the radiation tolerance was 
observed for cartilage and spinal cord in earlier studies with hypoxic sensitisation, 
the total dose to the larynx and the spinal cord in the ARCON arm was limited to 64 
and 40 Gy, respectively.19,20 Patients allocated to the ARCON arm received carbogen 
(98% O2 + 2% CO2, 4 minutes before and during radiotherapy) and nicotinamide (60 
mg/kg, 1-1.5 hours before fractions) concurrently with radiotherapy.21 Follow-up visits 
took place every 2, 3, 4 months during the first, second and third year respectively, 
then every 6 months for another 2 years. The larynx was assessed by fiberoptic or 
indirect laryngoscopy. Regional control was assessed by palpation of the neck. 
When tumour recurrence was suspected, imaging (CT-scan or MRI) was performed 
to document the extent of the disease and biopsies were taken for pathological 
confirmation. 
Approval for the study was obtained from the Radboud University Nijmegen Medical 
Centre Research Ethics Committee with ratification from each centre. Written informed 
consent was obtained before randomisation.
Volumetric analysis 
All pre-treatment CT-scans were evaluated by a head and neck radiologist. Contouring 
of the primary tumour and involved lymph nodes was reviewed by one experienced 
head and neck radiation oncologist. The majority of the imaging studies were 
performed during intravenous injection of contrast medium. A slice thickness of ≤ 3 
mm was used in most cases. For every CT-study, the outer margin of any abnormal 
laryngeal mass or involved lymph node was contoured on each image. Neck nodes 
were considered pathological in case of the presence of central necrosis on CT-scan 
and/or positive cytology and in case of a minimal axial diameter on CT-scan of more 
than 10 mm. Indications for a cytological punction were the presence of a lymph 
node with a short axis diameter *5 mm, the loss of a nodal hilum, a nodular shape or 
the presence of necrosis. Location of the initially involved and recurrent nodes to 
specific lymph node levels was assessed according to the consensus recommenda-
tions for delineation of node levels by Gregoire et al.22 The tumour volume was 
calculated automatically in cubic centimetres by multiplying the tumour areas by 
section thickness and intersection gap (summation-of-areas technique). 
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Endpoints 
Endpoints were local control (LC), regional control (RC) and  metastasis-free survival 
(MFS) at 5 years from randomisation. All intervals were calculated from the date of 
randomisation and censored after 60 months or at last follow-up. LC was defined as 
complete and persistent disappearance of the primary tumour after radiotherapy, 
and as freedom of first recurrence in the larynx, not including salvage procedures. 
RC was defined as complete and persistent disappearance of the pathological lymph 
node(s), and freedom of first recurrence in the lymph nodes after radiotherapy, not 
including salvage procedures. MFS was defined as the time from randomisation to 
distant metastasis. In addition, an analysis per individual lymph node was performed, 
which is referred to as nodal control (NC).  
Statistical Methods 
Statistical analyses were performed using SPSS 19.0 for Mac. Mann-Whitney U and 
Chi-square tests, where appropriate, were used at a two-sided significance level of 
.05. Kaplan-Meier plots with log-rank testing and Cox proportional hazard models 
were used to investigate the impact of volume on radiotherapy outcome. Tumour 
volume was analysed as a continuous variable, by receiver operating characteristic 
(ROC analysis) and by dichotomisation at previously described cut-off values of 3.5 
cm3 for glottic and 6.0 cm3 for supraglottic tumours, and by the median for nodal 
volume.5,8
Role of the funding source
The study sponsors had no role in the study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access 
to all of the data and the final responsibility to submit for publication. 
Results
Patient Characteristics 
Between April 2001 and February 2008, 345 patients were randomised to either AR 
(n=174) or ARCON (n=171). Pre-treatment CT-scans of 270 patients (AR, n=137; 
ARCON, n=133) were available for tumour volume calculation. For technical reasons, 
pre-treatment CT-scans could not be used or restored in the remaining 75 patients. 
The median follow-up time was 44 months (range 2-84) and 59 (range18-84) months 
for the whole group and for patients still alive, respectively. Median age was 60 years 
for AR and ARCON patients. Male/female ratio was 109/28 and 108/25 for AR and 
ARCON, respectively. Tumour characteristics were well balanced without significant 
differences between the treatment arms (Table 1). 
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Primary tumour volume
A correlation between the primary tumour volume and T-stage was observed (Rs=.51, 
P <.01). In both treatment arms no correlation was found between the primary tumour 
volume and local control (LC), regional control (RC) or metastasis-free survival (MFS) 
when a cut-off value of 3.5 cm3 for glottic and 6.0 cm3 for supraglottic tumours was 
used (Figure 1).  Similar observations were done when volume was analysed as a 
continuous variable or by ROC analysis (data not shown). In an exploratory subgroup 
Table 1   Tumour characteristics.
Characteristics AR ARCON P a 
 (N=137) (N=133)  
Site of the primary tumour - no. (%) .49
Glottic 57 (42) 56 (42)
Supraglottic 80 (58) 77 (58)
AJCC stage groupings - no. (%) .85
Stage II 41 (30) 36 (27)
Stage III 56 (41) 59 (44)
Stage IV 40 (29) 38 (29)
T-stage - no. (%) .79
T2 50 (37) 43 (32)
T3 69 (50) 74 (56)
T4 18 (13) 16 (12)
N-stage - no. (%) .89
N0 93 (68) 90 (68)
N1 18 (13) 16 (12)
N2a 2 (1) 2 (1)
N2b 8 (6) 6 (5)
N2c 16 (12) 19 (14)
N3 0 (0) 0 (0)
Primary tumour volume in cm3 - range (median) .79
Glottic .3 - 34.8 (3.6) .3 - 49.9 (3.0)
Supraglottic 2.1 - 37.5 (11.1) .8 - 42.7 (10.8)
Total nodal volume in cm3 - range (median) .4 - 57.7 (3.6) 1.0 - 65.2 (3.5) .80
a Chi-Square test
502026-L-sub01-bw-Janssens
83
Tumour volume in laryngeal cancer
5
analysis we also did not find a correlation between primary tumour volume and local 
control rate when stratified for T-stage.
Lymph node volume 
Eighty-seven patients had pathological lymph nodes and the total number of involved 
lymph nodes in these patients was 165.
Figure 1  No correlation is observed between the primary tumour volume at glottic or 
supraglottic subsite and the local control for patients treated by AR or ARCON.
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A strong correlation between total nodal volume and N-stage was found (Rs=.93, 
P <.01). The total nodal cut-off value of 3.5 cm3 in the current study, which corresponds 
to a sphere with a diameter of 2.0 cm, is based on the median value of the total nodal 
volumes. The presence of pathological lymph nodes (N0 vs. N+) was a poor 
prognostic factor for RC (Figure 2). However, in the AR and ARCON groups total 
nodal volume (< 3.5 cm3 vs. > 3.5 cm3) was not associated with a poorer RC. MFS 
of patients with neck level IV involvement was worse compared to other patients, 
independent of treatment regimen (P <.01). 
When an analysis based on individual lymph nodes was performed, an inferior 5 year 
nodal control rate was observed in both treatment arms for larger nodal volumes with 
a cut-off value of 3.5 cm3 (AR: 79% vs. 54%, P <.01 and ARCON: 98% vs. 80%, P .02). 
Regional control was in favour of ARCON for nodal volumes < 3.5 cm3 (AR: 79% vs.
ARCON: 98%, P <.01) and volumes > 3.5 cm3 (AR: 54% vs. ARCON: 80%, P <.01) 
(Figure 3).
Figure 2  The presence of pathological lymph nodes is a poor prognostic factor for 
regional control, while larger total nodal volume was not associated with a poorer 
regional control.
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The strong prognostic value of primary tumour volume, observed in several 
retrospective analyses was not confirmed in patients with cT2-4 laryngeal cancer 
treated in a large prospective randomised trial with accelerated radiotherapy with or 
without carbogen breathing and nicotinamide.3-9
Repeated analyses reported by the University of Florida demonstrated that 
pre-treatment based CT-volumes smaller than 3.5 cm3 for glottic and 6.0 cm3 for 
supraglottic tumours resulted in a significant better local control.5-9 One possible 
explanation for the absence of a volume effect in the current study might be the 
reduction of overall treatment time by the use of accelerated radiotherapy for all 
patients. This approach has demonstrated superior loco-regional tumour control 
rates in several head and neck cancer trials.23-25 With conventional fractionation 
schedules local control rates are in the order of 67-80%, 30-77% and 26-52% for T2, 
T3 and T4 tumours, respectively.26-30 A previous analysis of the current study failed to 
show a correlation between local tumour control and T-stage, even when glottic and 
supraglottic tumors were analysed separately.17 These observations indicate that 
patients with more advanced T-stages and larger tumour volumes profit most from 
accelerated fractionation. Evidence for this has recently been published by Soliman 
Figure 3  Based on individual lymph node analyses, nodal control was in favour of 
ARCON, irrespective of nodal volume.
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et al. for a large cohort of lung cancer patients from the CHARTWEL trial (Continuous 
Hyperfractionated-Accelerated RadioTherapy WEekend-Less) treated in one single 
institution.31 In this randomised trial, the conventional dose of 66 Gy in 33 daily 
fractions of 2 Gy over 6.5 weeks was compared to 60 Gy in 40 fractions of 1.5 Gy, 3 
fractions per day, over 18 days. CHARTWEL was increasingly more efficient relative 
to conventional fractionation with increasing tumour volume. The authors speculated 
that larger tumours may have a higher capacity to repopulate during radiotherapy, 
e.g. because they might be more hypoxic and more cancer stem cells might start 
rapid repopulation after radiation induced reoxygenation. Another important reason 
for the lack of correlation between tumour volume and local control can be explained 
by methodology. The current analysis is based on a large cohort of tumours treated 
in a homogenous way by 3D-conformal radiotherapy in thermoplastic masks and 
position verification. Although tumour volume calculations in the retrospective studies 
are based on diagnostic CT-or MR imaging, the radiotherapy treatment planning was 
performed based on conventional 2D equipment.3-9 Despite the use of accelerated or 
hyperfractioned radiotherapy regimens, it might be that larger tumours in particular 
are subjective to local failures by underestimating tumour extension due to the 
2D-treatment planning and lack of position verification systems.3-9  
It has also been demonstrated by a limited number of reports that increasing nodal 
volume, based on the total volume of all neck nodes, is associated with poor RC.13-16 
Although the presence of pathological lymph nodes in the current study was a poor 
prognostic factor for regional control, no correlation between total nodal volume and 
RC was observed in both treatment arms. This could be explained by the high 
regional control rates and the limited number of events. To increase the study size 
and number of events, an additional analysis per lymph node was performed. This 
time, an inferior 5 year nodal control rate was observed in both treatment arms for 
increasing nodal volumes. The additional analysis also demonstrated that ARCON 
improved nodal control for nodal volumes up to 3.5 cm3 and larger compared to AR. 
This observation in a well-balanced group of glottic and supraglottic patients with 
pathologic neck nodes, receiving similar doses of radiotherapy in both treatment 
arms, supports the role of hypoxia in the occurrence of regional failure. In the 
DAHANCA 6&7 trial, a benefit of regional control was not observed by increasing the 
number of fractions per week from 5 to 6, suggesting a minor contribution of 
repopulation in the neck nodes.24 Our study is the first reported prospective 
randomised trial employing a treatment that is able to correct the poor outcome of 
increasing nodal volume in a homogenous cohort of head and neck cancer patients. 
Nodal volume calculation remains difficult to compare with literature for multiple 
reasons (32). Reports are retrospective and combine different head and neck 
subsites with a different radiosensitivity such as HPV or EBV positive and negative 
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tumours.33,34 Reports also use a variety of treatment strategies and methods for 
measuring volumes (sphere and ellipsoid formula, summation-of-areas technique). 
Moreover, nodal volumes, as a separate entity, are reported only in a minority of 
papers using different endpoints (loco-regional control, regional control, metasta-
sis-free survival, overall survival). Although the maximal diameter of regional lymph 
nodes is far from an accurate measure of tumour load in the neck, today it remains 
the standard for decision making on additional neck dissection or chemo-radiother-
apy in daily practice.10-12 
Conclusion
The strong prognostic value of primary tumour volume, observed in a number of 
retrospective analyses was not confirmed in patients treated in this prospective 
randomised trial with 3D-conformal, accelerated radiotherapy ± carbogen breathing 
and nicotinamide. In patients with pathological lymph nodes, a correlation between 
total nodal volume and regional control was lacking as well. Additional analyses 
based on individual nodal volumes demonstrated an inferior nodal control with 
increasing nodal volume for both regimens. However, a significant benefit in nodal 
control was observed in favour of ARCON. 
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Abstract 
Background
To report on health-related quality-of-life (HRQoL) of 345 patients with cT2-4  laryngeal 
cancer, treated in a randomized trial comparing accelerated radiotherapy with 
carbogen and nicotinamide (ARCON) against accelerated radiotherapy alone (AR).
Methods
HRQoL was assessed using the European Organisation for Research and Treatment 
of Cancer (EORTC) HRQoL Questionnaire-C30 (QLQ-C30) and the Head & Neck 
cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and at 6, 12, 
and 24 months post-baseline. Data were analyzed two years after inclusion of the last 
patient. 
Results 
Local tumor control at 5 years was 78% for AR versus 79% for ARCON. Moderate to 
severe clinical impact of the treatment was observed for nearly all items of the 
QLQ-C30 and QLQ-H&N35 between baseline and end of treatment. At 6 months, 
scores returned to baseline level with exception of dry mouth, sticky saliva, and taste/
smell. No difference in HRQoL score between AR and ARCON was observed. At 2 
years from baseline, the percentage of patients reporting moderate to severe 
complaints of dry mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 
18%, respectively, while the majority of patients had no or few complaints of swallowing 
(79%) or speech (64%). The use of a feeding tube at 2 years from diagnosis was 
limited to 5% of patients. 
Conclusions
With accelerated radiotherapy, high local tumor control was obtained while maintaining 
good speech and swallowing function. Long-term dry mouth, sticky saliva and changes 
in taste/smell are limited to one quarter of patients.
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Introduction
Treatment of patients with head and neck cancer has a significant impact on 
health-related quality-of-life (HRQoL). A substantial percentage of survivors will suffer 
from long-term disease specific side effects (e.g. xerostomia, sticky saliva and 
dysphagia) and general adverse symptoms like fatigue, difficulties in social 
functioning and mental problems (1,2,3,4,5,6). In head and neck cancer, there has 
been a shift from surgery towards organ preservation strategies over the last decades. 
These strategies comprise of radiotherapy with altered fractionation schedules and 
concomitant chemoradiotherapy, sometimes even combined with neoadjuvant 
chemotherapy (7,8). The price for these intensified regimens is increased acute and 
long-term toxicity (9,10). A balanced decision-making between increased toxicity and 
modest improvements in tumor control is often difficult for patients and treating 
physicians. Thus, proper knowledge of HRQoL is essential to understand the real 
benefit of any new regimen. For this reason questionnaires on HRQoL have been fully 
integrated in the majority of phase III trials (11). The European Organisation for 
Research and Treatment of Cancer (EORTC) Questionnaire-C30 (QLQ-C30) and the 
Head&Neck cancer module (QLQ-H&N35) are amongst the most commonly used 
questionnaires (12,13,14). Although an increasing number of studies on HRQoL from 
clinical trials in head and neck cancer is being published, prospectively collected 
long-term data on large and homogeneous populations like patients with advanced 
laryngeal cancer are still sparse (1,3,4,15,16). 
Recently it was demonstrated in a randomized phase III trial that the addition of 
carbogen breathing and nicotinamide to accelerated radiotherapy (ARCON) in 
patients with T2-4 laryngeal cancer results in a 87% larynx preservation rate and a 
benefit of 8% in regional control compared to accelerated radiotherapy (AR) alone 
(17). In subgroups (hypoxic tumors, anemic patients) the gain was significantly larger 
(17,18). Accelerated radiotherapy counteracts tumor cell repopulation whereas 
carbogen breathing and nicotinamide reduce hypoxic radioresistance (19). There 
was a good compliance rate with carbogen breathing (86%) and nicotinamide (80%) 
and similar acute and late toxicity profiles were observed between the arms of the 
study (20). Information on HRQoL can help to further determine the real therapeutic 
benefit of ARCON and may assist in decision-making regarding larynx preservation 
treatments for patients with advanced laryngeal cancer.
This paper reports on the impact of AR and ARCON on HRQoL in patients presenting 
with locally advanced laryngeal cancer.
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Methods
Study Design and Eligibility
This was an open-label, randomized phase III trial comparing AR with ARCON in 
patients with cT2-4 laryngeal cancer. The trial (ClinicalTrials.gov NCT00147732) was 
conducted under the auspices of the Dutch Head and Neck Society in 7 centers in 
the Netherlands and the UK (Table S1). Eligibility criteria are provided in the 
supplementary Table S2.
Approval for the study was obtained from the Radboud University Medical Centre 
Research Ethics Committee Nijmegen with ratification from each center. Written 
informed consent was obtained before randomization.
Randomization
Patients were centrally randomized by phone at the IKO (“Integraal Kankercentrum 
Oost”) trials office. Treatment arm assignments (AR vs ARCON) were stratified for 
tumor site (glottic vs supraglottic) and institution. A dynamic allocation method was 
used to avoid imbalance of treatment assignment within an institution. Randomization 
took place after completion of all study investigations and no longer than 4 weeks 
prior to the anticipated start of treatment.
Treatment
A radiation dose of 44 Gy in 22 daily fractions of 2 Gy was prescribed to the primary 
tumor and regional neck nodes followed by a boost dose of 24 Gy in twice daily 
fractions of 2 Gy to the primary tumor and involved lymph nodes. Details on target 
volume and technique are described earlier (17,20). Because a decrease in the 
radiation tolerance was observed for cartilage and spinal cord in earlier studies with 
hypoxic sensitization, the total dose to the arytenoid cartilage and the spinal cord in 
the ARCON arm was limited to 64 and 40 Gy, respectively (21,22). 
Patients allocated to the ARCON arm received carbogen (98% O2 + 2% CO2, 4 
minutes before and during radiotherapy) and nicotinamide (60 mg/kg, 1-1.5 hours 
before fractions) concurrently with radiotherapy. Details of the procedure are described 
previously (17,20). 
All patients participating in this study were treated in academic centers with 
accreditation for head and neck oncology by the Dutch Head and Neck Society and 
employing institution-wide quality assurance programs.
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Health Related Quality-of-Life
The validated EORTC quality-of-life core measure Questionnaire-C30 (QLQ-C30, 
version 3) and the disease-specific Head & Neck cancer module (QLQ-H&N35) were 
used (12,13,14). The QLQ-C30 comprises 5 functional scales (physical, cognitive, 
emotional, social and role), a global quality-of-life scale, 3 symptom scales (pain, 
fatigue and nausea/vomiting) and 6 single items (dyspnea, insomnia, appetite loss, 
constipation, diarrhea and financial difficulties). The QLQ-H&N35 is composed of 
7 symptom scales (pain, swallowing, senses, speech, social eating, social contact 
and sexuality), 6 symptom items (teeth, trismus, dry mouth, sticky saliva, cough and 
feeling ill) and 5 additional items concerning the use of pain medication, nutritional 
supplements, feeding tube and weight loss or weight gain.
Questions on both HRQoL measures were scaled and scored using the recommended 
EORTC Quality-of-Life Group procedures (23). Raw scores were transformed to a 
linear scale ranging from 0 to 100. A higher score represents a higher level of 
functioning or a higher level of symptoms. Evidence-based guidelines were developed 
for QLQ-C30 to classify differences from trivial to large (24). For the interpretation of 
the QLQ-H&N35 questionnaires, mean changes of <10 effect-points were considered 
as no or small changes in QoL. Mean changes of >20 points were classed as large 
effects in QoL (25). 
Monitoring During Treatment and Follow-up Evaluations
At baseline, at completion of radiotherapy and at 6, 12, and 24 months post-baseline, 
quality-of-life was assessed using the QLQ-C30 and the QLQ-H&N35 questionnaires. 
Follow-up visits took place every 2, 3, 4 months during the first, second and third year 
respectively, then every 6 months for another 2 years. The larynx was assessed by 
fiberoptic or indirect laryngoscopy. Regional control was assessed by palpation of 
the neck. When tumor recurrence was suspected, imaging (CT-scan or MRI) was 
performed to document the extent of the disease and biopsies were taken for 
pathological confirmation. HRQoL assessments after salvage procedures were not 
included in this analysis.
Endpoints and Statistics
The primary endpoint of the randomized trial was local control. Intervals were 
calculated from the date of randomization and censored after 60 months or at last 
follow-up. Local Control (LC) and regional control (RC) were defined as freedom of 
first recurrence at the primary tumor site or neck and complete and persistent 
disappearance of the pathological lymph nodes after radiotherapy, not including 
salvage procedures. Compliance levels on QoL were calculated based on the number 
of questionnaires received divided by the number of questionnaires expected at each 
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assessment point. For every patient without tumor-related event, in follow-up with 
QoL assessment at baseline, a questionnaire was expected. Patients were evaluable 
for QoL assessment if at least the baseline questionnaire and one additional 
questionnaire, prior to disease recurrence, were available.
Statistical analyses were performed using SPSS 19.0.0 for Mac. Changes in symptoms 
and QoL items were evaluated with a repeated measures ANOVA using a mixed 
effect modeling procedure. F-tests were used for testing main effects of group and 
time, and an interaction effect of group x time. For comparison of continuous variables 
between the study arms the Mann-Whitney test was used. Differences in compliance 
between arms was tested using the Fisher’s exact test. The level of statistical 
significance was set at P = .05. 
Role of the funding source
The study sponsors had no role in the study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access 
to all of the data and the final responsibility to submit for publication.
Results
Patient Characteristics and Tumor-related Outcome
Between April 2001 and February 2008, 345 patients were randomized to either AR 
(n=174) or ARCON (n=171) (Figure 1). Patient demographics and clinical tumor 
 characteristics were well balanced without significant differences between the 
treatment arms (Table 1). After a median follow-up of 44 months, local tumor control 
rate at 5 years was 78% for AR versus 79% for ARCON (P = .80) with corresponding 
larynx preservation rates of 84% and 87% (P = .48). The 5-year regional control was 
significantly better with ARCON compared to AR (93% vs. 86%, P = .04). AR and 
ARCON produced equal levels of acute and late toxicity (17,20). Twelve patients in the 
AR group and 6 patients in the ARCON group received a tracheostomy for severe 
edema with dyspnea and/or stridor. All 27 (AR: n=15, ARCON: n=12) patients who 
developed a cartilage necrosis could be managed conservatively. Four of them did 
receive a tracheostomy (AR: n=1, ARCON: n=3) and there was no need for 
laryngectomy.
Compliance 
The overall compliance with completion of questionnaires was 78% at baseline, 68% 
at the end of treatment, 70%, 70% and 65% at 6, 12, and 24 months, respectively. 
Compliance for patients treated by AR or ARCON at different time points is listed in 
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Table 2. No significant difference was observed between both treatment arms. 
HRQoL data on 76 patients were excluded from analysis due to missing data at 
baseline (N=40), at a subsequent assessment moment (N=18) or at any moment of 
assessment (N=18). No difference in patient, tumor and treatment characteristics 
was observed between included and excluded patients (Mann-Whitney or Fisher’s 
exact tests of age, sex, tumor site, T, N, M, stage and treatment arm).  
  
EORTC QLQ-C30, version 3.0
Moderate to large differences were observed between baseline and end-of-treat-
ment measurements in 10 out of 15 items (Figure 2). Large clinical effects were 
observed for role functioning, global health, fatigue, nausea/vomiting, pain and loss 
of appetite, all to the worse. Moderate differences were observed for physical-, 
cognitive-, and social functioning, as well as constipation. No significant differences 
were observed between patients treated by AR or ARCON. At 6 months post-baseline 
Figure 1  CONSORT diagram.
Randomly assigned (N=345) 
Allocated to AR (N=174) Allocated to ARCON (N=171)
Received allocated intervention (N=174) Received allocated intervention (N=170)
Did not receive allocated intervention (N=0) Did not receive allocated intervention (N=1)
incorrect diagnosis (N=1)
 
Analyzed (N=136) Analyzed (N=133) 
Excluded from QoL analysis (N=38) Excluded from QoL analysis (N=38) 
Missing data at baseline (N=21) 
Missing data at subsequent assessment (N=7) 
No data available (N=10) 
Missing data at baseline (N=19) 
Missing data at second assessment (N=11) 
No data available (N=8) 
AR: Accelerated Radiotherapy
ARCON: Accelerated Radiotherapy with Carbogen and Nicotinamide  
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all items returned to baseline level, except fatigue and cognitive functioning (both 
small differences compared to baseline). At 24 months insomnia was slightly less 
compared to baseline score (P < .01) (Figure 2K).     
Table 1   Patient demographics and clinical tumor characteristics (N=345).
Characteristics AR ARCON P 
 (N=174) (N=171)  
Age - yr 0.56a
Median 60 61
Range 38-88 41-84
Sex - no. (%) 0.16b
Male 136 (78) 142 (83)
Female 38 (22) 29 (17)
Performance status - no. (%) 0.54b
0 140 (80) 137 (81)
1 34 (20) 34 (19)
Site of the primary tumor - no. (%) 0.49b
Supraglottic 100 (57) 97 (56)
Glottic 74 (43) 74 (44)
AJCC stage groupings - no. (%) 0.35b
Stage II 53 (31) 46 (27)
Stage III 65 (37) 77 (45)
Stage IV 56 (32) 48 (28)
T-stage - no. (%) 0.20b
T2 67 (38) 55 (32)
T3 80 (46) 95 (56)
T4 27 (16) 21 (12)
N-stage - no. (%) 0.58b
N0 117 (67) 116 (68)
N1 20 (12) 23 (13)
N2a 4 (2) 7 (4)
N2b 10 (6) 5 (3)
N2c 23 (13) 20 (12)
N3 0 (0) 0 (0)  
a Mann-Whitney U test
b Chi-Square test
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EORTC QLQ-H&N35
Large clinical impact (> 20 points difference) was observed for the majority of items 
between baseline and end of treatment (Figure 3) but also for this disease-specific 
HRQoL scoring no differences between AR and ARCON were observed. At 6 months, 
scores returned to baseline level for all items with exception of dry mouth, sticky 
saliva, and taste/smell (Figure 3C, 3J, 3K). For the latter items, further improvement 
was observed at 12 and 24 months with a return to baseline levels for the majority of 
patients with dry mouth and sticky saliva. At 2 years, the percent of patients reporting 
“quite a bit” or “very much” complaints of dry mouth, sticky saliva, or changes in 
taste- and smell perception was 30%, 22% and 18%, respectively. 
Speech and swallowing 
Up to 12 months post-baseline, swallowing function improved to baseline level 
whereas speech continued to improve in the second year and went on to exceed 
Table 2   Compliance with questionnaires at each assessment point for patients 
treated by AR and ARCON (N=345).
Characteristics AR ARCON P a 
(N=174) (N=171)
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At Baseline 136 174 78 133 171 78 0.76
At completion of radiotherapy 114 173 66 119 169 70 0.37
At 6 months 109 159 69 115 159 72 0.46
At 12 months 93 136 68 99 139 72 0.61
At 24 months 69 115 60 79 113 70 0.12
a Fisher’s exact test
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Figure 2  EORTC QLQ-C30, version 3.0, average score (Y-axis) for AR (blue line) and 
ARCON (green line) patients at baseline, at completion of radiotherapy and at 6, 12, 
and 24 months post-baseline (X-axis). Moderate to severe changes were observed 
between baseline and end of treatment measurements in 10 out of 15 items. At 6 months 
small differences are still observed for cognitive functioning (E) and fatigue (G).
A                                Global Health B                      Physical functioning 
F                         Social functioning E                   Cognitive functioning 
I                                                 Pain J                                         Dyspnoe 
M                                Constipation N                                          Diarree 
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Figure 2 (Continued) At 24 months insomnia (K) was slightly less compared to 
baseline scores. No significant differences were observed between patients treated 
by AR or ARCON. Statistically significant changes relative to baseline are indicated 
by , the arrow indicates improvement, i.e. a higher level of functioning or less 
symptoms.
C                            Role functioning D                   Emotional functioning 
G                                          Fatigue H                   Nausea and vomiting 
K                                       Insomnia L                               Appetite Loss 
O                     Financial difficulties 
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Figure 3  EORTC QLQ-H&N35, average score (Y-axis) for AR (blue line) and ARCON 
(green line) patients at  baseline, at completion of radiotherapy and at 6, 12, and 
24 months post-baseline (X-axis). At 6 months, scores returned to baseline level 
for all items with exception of, taste- and smell perception (C), dry mouth (J), sticky 
saliva (K).
 A                                                 Pain  B                                       Swallowing  C                                       Taste/smell 
F                                Social Contact  G                                Less Sexuality H                                                Teeth 
K                                    Sticky Saliva L                                         Coughing M                                               Felt ill 
P                                   Feeding Tube Q                                 Weight Loss R                                     Weight Gain 
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Figure 3 (Continued) Swallowing function (B) improved to baseline level but not 
further thereafter. Speech (D) continued to improve in the second year and went on 
to exceed pre-treatment levels. Statistically significant changes relative to baseline are 
indicated by , the arrow indicates improvement, i.e. a higher level of functioning or 
less symptoms.
D                                             
Speech 
E                    Social Eating 
I                                 Opening Mouth J                                         Dry Mouth 
N                                      Pain Killers O               Nutritional Supplements 
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Table 3   Tumor- and patient related factors (median) with potential impact on  
QLQ-H&N35 score for speech and swallowing at different time-points  
(in bold: P = < .05).
Speech Swallowing
   Baseline End RT 6m 12m 24m     Baseline End RT 6m 12m 24m 
T-stage T2-3 vs T4 AR 33 vs 56 67 vs 72 22 vs 22 11 vs 56 17 vs 22 T-stage T2-3 vs T4 AR 8 vs 4 75 vs 71 17 vs 25 8 vs 17 8 vs 8
ARCON 44 vs 67 56 vs 44 22 vs 33 22 vs 33 22 vs 0 ARCON 8 vs 25 75 vs 58 17 vs 17 17 vs 25 8 vs 8
All 33 vs 56 67 vs 67 22 vs 33 22 vs 33 22 vs 22 All 8 vs 8 75 vs 67 17 vs 17 8 vs 21 8 vs 8
N-stage N0 vs N+ AR 33 vs 44 67 vs 67 22 vs 22 11 vs 22 22 vs 11 N-stage N0 vs N+ AR 8 vs 25 75 vs 67 17 vs 25 8 vs 17 8 vs 13
ARCON 44 vs 44 67 vs 56 22 vs 22 22 vs 33 22 vs 22 ARCON 8 vs 25 67 vs 75 17 vs 17 17 vs 17 8 vs 8
All 44 vs 44 67 vs 56 22 vs 22 22 vs 22 22 vs 19 All 8 vs 25 75 vs 75 17 vs 24 8 vs 17 8 vs 8
Site Glottic  
vs Supraglottic
AR 44 vs 33 67 vs 67 22 vs 22 11 vs 22 22 vs 19 Site Glottic  
vs Supraglottic
AR 0 vs 25 75 vs 75 17 vs 17 8 vs 17 8 vs 8
ARCON 56 vs 33 67 vs 56 22 vs 22 22 vs 33 22 vs 22 ARCON 0 vs 25 63 vs 75 17 vs 25 8 vs 17 8 vs 13
All 44 vs 33 67 vs 56 22 vs 22 11 vs 22 22 vs 22 All 0 vs 25 67 vs 75 17 vs 22 8 vs 17 8 vs 8
T-volume Supraglottic  
( < vs > 6 cm3)
AR 33 vs 33 67 vs 67 22 vs 22 17 vs 22 22 vs 11 T-volume Supraglottic  
( < vs > 6 cm3)
AR 8 vs 17 75 vs 75 17 vs 25 8 vs 8 8 vs 8
Glottic  
(< vs > 3.5 cm3)
ARCON 44 vs 44 61 vs 56 22 vs 22 22 vs 33 17 vs 22 Glottic  
(< vs > 3.5 cm3)
ARCON 8 vs 25 58 vs 75 17 vs 17 17 vs 17 8 vs 8
All 39 vs 44 67 vs 67 22 vs 22 22 vs 22 22 vs 14 All 8 vs 17 67 vs 75 17 vs 19 8 vs 11 8 vs 8
PS 0 vs 1 AR 33 vs 50 67 vs 78 22 vs 22 22 vs 28 22 vs 6 PS 0 vs 1 AR 8 vs 25 67 vs 83 17 vs 21 8 vs 8 8 vs 0
ARCON 44 vs 56 56 vs 61 22 vs 22 22 vs 33 22 vs 22 ARCON 8 vs 21 75 vs 71 17 vs 17 17 vs 17 8 vs 29
All 33 vs 56 56 vs 72 22 vs 22 22 vs 33 22 vs 17 All 8 vs 25 75 vs 75 17 vs 17 8 vs 17 8 vs 8
Age <70 vs >70 AR 33 vs 44 67 vs 78 22 vs 33 22 vs 22 22 vs 19 Age <70 vs >70 AR 8 vs 8 75 vs 83 17 vs 50 8 vs 21 8 vs 25
ARCON 44 vs 44 56 vs 61 22 vs 33 22 vs 33 22 vs 33 ARCON 17 vs 0 75 vs 67 22 vs 17 17 vs 11 8 vs25
All 44 vs 44 56 vs 67 22 vs 33 22 vs 33 22 vs 22 All 8 vs 4 75 vs 75 17 vs 20 8 vs 17 8 vs 25
Gender Male vs Female AR 33 vs 33 67 vs 67 22 vs 17 11 vs 22 19 vs 22 Gender Male vs Female AR 8 vs 25 67 vs 75 17 vs 17 8 vs 8 8 vs 8
ARCON 44 vs 56 56 vs 78 22 vs 33 22 vs 33 22 vs 11 ARCON 8 vs 25 67 vs 83 17 vs 29 10 vs 25 8 vs 22
  All 44 vs 39 67 vs 67 22 vs 22 22 vs 22 22 vs 17    All 8 vs 25 67 vs 75 17 vs 19 8 vs 17 8 vs 8
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Table 3   Tumor- and patient related factors (median) with potential impact on  
QLQ-H&N35 score for speech and swallowing at different time-points  
(in bold: P = < .05).
Speech Swallowing
   Baseline End RT 6m 12m 24m     Baseline End RT 6m 12m 24m 
T-stage T2-3 vs T4 AR 33 vs 56 67 vs 72 22 vs 22 11 vs 56 17 vs 22 T-stage T2-3 vs T4 AR 8 vs 4 75 vs 71 17 vs 25 8 vs 17 8 vs 8
ARCON 44 vs 67 56 vs 44 22 vs 33 22 vs 33 22 vs 0 ARCON 8 vs 25 75 vs 58 17 vs 17 17 vs 25 8 vs 8
All 33 vs 56 67 vs 67 22 vs 33 22 vs 33 22 vs 22 All 8 vs 8 75 vs 67 17 vs 17 8 vs 21 8 vs 8
N-stage N0 vs N+ AR 33 vs 44 67 vs 67 22 vs 22 11 vs 22 22 vs 11 N-stage N0 vs N+ AR 8 vs 25 75 vs 67 17 vs 25 8 vs 17 8 vs 13
ARCON 44 vs 44 67 vs 56 22 vs 22 22 vs 33 22 vs 22 ARCON 8 vs 25 67 vs 75 17 vs 17 17 vs 17 8 vs 8
All 44 vs 44 67 vs 56 22 vs 22 22 vs 22 22 vs 19 All 8 vs 25 75 vs 75 17 vs 24 8 vs 17 8 vs 8
Site Glottic  
vs Supraglottic
AR 44 vs 33 67 vs 67 22 vs 22 11 vs 22 22 vs 19 Site Glottic  
vs Supraglottic
AR 0 vs 25 75 vs 75 17 vs 17 8 vs 17 8 vs 8
ARCON 56 vs 33 67 vs 56 22 vs 22 22 vs 33 22 vs 22 ARCON 0 vs 25 63 vs 75 17 vs 25 8 vs 17 8 vs 13
All 44 vs 33 67 vs 56 22 vs 22 11 vs 22 22 vs 22 All 0 vs 25 67 vs 75 17 vs 22 8 vs 17 8 vs 8
T-volume Supraglottic  
( < vs > 6 cm3)
AR 33 vs 33 67 vs 67 22 vs 22 17 vs 22 22 vs 11 T-volume Supraglottic  
( < vs > 6 cm3)
AR 8 vs 17 75 vs 75 17 vs 25 8 vs 8 8 vs 8
Glottic  
(< vs > 3.5 cm3)
ARCON 44 vs 44 61 vs 56 22 vs 22 22 vs 33 17 vs 22 Glottic  
(< vs > 3.5 cm3)
ARCON 8 vs 25 58 vs 75 17 vs 17 17 vs 17 8 vs 8
All 39 vs 44 67 vs 67 22 vs 22 22 vs 22 22 vs 14 All 8 vs 17 67 vs 75 17 vs 19 8 vs 11 8 vs 8
PS 0 vs 1 AR 33 vs 50 67 vs 78 22 vs 22 22 vs 28 22 vs 6 PS 0 vs 1 AR 8 vs 25 67 vs 83 17 vs 21 8 vs 8 8 vs 0
ARCON 44 vs 56 56 vs 61 22 vs 22 22 vs 33 22 vs 22 ARCON 8 vs 21 75 vs 71 17 vs 17 17 vs 17 8 vs 29
All 33 vs 56 56 vs 72 22 vs 22 22 vs 33 22 vs 17 All 8 vs 25 75 vs 75 17 vs 17 8 vs 17 8 vs 8
Age <70 vs >70 AR 33 vs 44 67 vs 78 22 vs 33 22 vs 22 22 vs 19 Age <70 vs >70 AR 8 vs 8 75 vs 83 17 vs 50 8 vs 21 8 vs 25
ARCON 44 vs 44 56 vs 61 22 vs 33 22 vs 33 22 vs 33 ARCON 17 vs 0 75 vs 67 22 vs 17 17 vs 11 8 vs25
All 44 vs 44 56 vs 67 22 vs 33 22 vs 33 22 vs 22 All 8 vs 4 75 vs 75 17 vs 20 8 vs 17 8 vs 25
Gender Male vs Female AR 33 vs 33 67 vs 67 22 vs 17 11 vs 22 19 vs 22 Gender Male vs Female AR 8 vs 25 67 vs 75 17 vs 17 8 vs 8 8 vs 8
ARCON 44 vs 56 56 vs 78 22 vs 33 22 vs 33 22 vs 11 ARCON 8 vs 25 67 vs 83 17 vs 29 10 vs 25 8 vs 22
  All 44 vs 39 67 vs 67 22 vs 22 22 vs 22 22 vs 17    All 8 vs 25 67 vs 75 17 vs 19 8 vs 17 8 vs 8
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pre-treatment levels (Figure 3B, 3D). At 2 years from diagnosis, 64% of the patients in 
both treatment arms, had “not at all” or “a little” complaints of speech and the 
percentage of patients with severe hoarseness, severe troubles talking to other 
people or troubles talking on the telephone (all score 4) was 14%. Seventy-nine 
percent of patients had “not at all” or “a little” swallowing problems. The use of a 
feeding tube at 2 years from diagnosis was limited to 5% of all patients. There was a 
trend towards more frequent use of tube feeding in patients age >70 years (3% vs 
14%; P = .07).  None of these items differed significantly between the AR and ARCON 
treated patients.
Tumor- and patient related factors (T-stage, N-stage, subsite, T-volume, performance 
status, age and gender) with potential impact on quality of speech and swallowing 
were analyzed separately (Table 3). At baseline, a clinically significant difference in 
speech was observed in favor of T2-3 versus T4-stage (P < .01) and supraglottic 
versus glottic tumors (P < .01). Quality of swallowing at baseline was negatively 
influenced by the presence of pathological lymph nodes (P < .01), supraglottic tumor 
site (P < .01), larger primary tumor volume (P < .01),  female gender (P < .01), and 
impaired performance status (P < .05). Female patients had more speech and 
swallowing problems at completion of radiotherapy, especially when receiving 
ARCON (P < .01). During the two years after treatment swallowing problems settled 
and decreased to baseline levels, except in the elderly (> 70 years of age) group (at 
24 months, P < .01). In patients presenting with T4 tumors long-term function of 
speech and swallowing was not impaired compared to those with T2-T3 tumors 
(speech: 65% vs 64%; P = 1.0 and swallowing: 75% vs 80%; P = 0.57). 
Discussion
This randomized trial, comparing accelerated radiotherapy alone with accelerated 
radiotherapy in combination with carbogen and nicotinamide for locally advanced 
laryngeal cancers, revealed similar changes in HRQoL for both treatment arms. After 
a transient period of clinically significant impairment for the majority of items in the 
core measure Questionnaire-C30 (QLQ-C30, version 3) and the disease-specific 
Head & Neck cancer module (QLQ-H&N35), a return to baseline levels was observed 
after 6 months for the majority of HRQoL items. However, subjective improvement of 
symptoms over time was less pronounced for dry mouth, and associated symptoms 
of sticky saliva and altered taste and smell. This pattern of HRQoL scores after 
treatment for head and neck cancers of various subsites has been observed by 
others as well (1,6,16).
502026-L-sub01-bw-Janssens
107
QoL after radiotherapy for laryngeal cancer
6
The main goal of primary radiotherapy for laryngeal cancer is to preserve speech and 
swallowing functions. However, preservation of organ anatomy does not necessary 
translate into preservation of organ function. Comprehensive and long-term data on 
organ function from prospective trials are sparse (3,4,26). Improving with time, at 2 
years after diagnosis the majority of patients treated in the current trial had no or just 
few complaints of speech whereas the percentage of patients with severe problems 
was less than 15%. Significantly impaired speech or voice quality at 2 years was 
reported in 3% to 8% of patients in the RTOG 91-11 trial, without significant difference 
between the three regimens (3,4). These percentages compare favorably to the 14% 
in the current study. The difference in favour of the RTOG 91-11 trial might be explained 
by the use of a different questionnaire and/or a higher rate of glottic tumors in the 
ARCON trial. Around 80% of patients treated in the current study reported no or just 
a little complaints of swallowing and only 5% used a feeding tube at 2 years from 
diagnosis. Feeding tube data were not collected in the RTOG 91-11 study, but inability 
to swallow was reported in less than 3% of patients (3,4). At 1 and 5 years from 
diagnosis, the RTOG-study 90-03 reported a much higher rate of tube feeding 
dependence of 13% after accelerated radiotherapy in a cohort of patients with head 
and neck cancer of various subsites (27). Conventional 3D-radiotherapy techniques 
were used for patients treated in the ARCON and RTOG-trials. With state-of-the-art 
intensity-modulated radiotherapy (IMRT) techniques, reduction of the radiation dose 
to uninvolved swallowing structures can be obtained. There is increasing evidence 
that IMRT results in a reduction of late swallowing toxicity and an improvement of 
patient functional outcomes (28,29). Thus, with current application of modern 
high-precision radiotherapy techniques it can be expected that functional outcome 
will further improve while tumor control rates remain high. 
While organ preservation positively affects HRQoL, xerostomia does not (30). 
Radiation induced xerostomia is the most commonly reported late side-effect of 
radiotherapy to the head and neck region (31). At 6 months, a return to baseline levels 
was observed in our study for the majority of HRQoL items with exception of dry 
mouth, and associated symptoms of sticky saliva and altered taste and smell. Similar 
outcomes were found by Nutting et al. who randomized patients with mainly 
oropharyngeal cancers between conventional radiotherapy and parotid sparing 
IMRT (2). At 2 years, grade *2 xerostomia was observed in 83% vs 29% of patients 
receiving conventional radiotherapy vs. IMRT, respectively. It is expected that the 30% 
rate of moderate to severe xerostomia, observed in the current study, will decrease 
with the use of IMRT. 
Potential patient- and tumor-related prognostic factors for functional outcome after 
larynx preservation were also studied. At baseline, more advanced T-stage, subsite, 
502026-L-sub01-bw-Janssens
108
presence of pathological lymph nodes, impaired performance status and female 
gender were correlated with impaired speech and/or swallowing. In all patients there 
was a complete remission of the primary tumor at the time of analysis resulting in 
significant improvements of these functions with time after treatment and at two years 
none of these clinical factors were correlated with larynx function anymore. Age older 
than 70 was the only factor associated with impaired recovery of swallowing function. 
Similar observations in older age groups have been made by others (9,32). 
Nevertheless, it should be mentioned that the vast majority of patients older than 70 
had a good functional outcome.
In patients presenting with T4 tumors, many head and neck oncologists are reluctant 
to use (chemo)radiotherapy and still prefer laryngectomy. Although chemotherapy 
can add to the toxicity profile of radiotherapy, this concern is mainly based on lower 
expected disease control rates and anticipated poor functional outcome (9,33,34). 
Recently, Rosenthal et al. demonstrated that the initial loco-regional control rate in a 
large cohort of 221 patients with T4 laryngeal cancer, was superior with upfront 
laryngectomy compared to larynx preservation approaches with chemoradiotherapy 
(34). However, ultimate loco-regional control was comparable because of the high 
percentage of successful surgical salvage procedures. Based on our data on 
long-term speech and swallowing, outcome of patients presenting with T4 tumors 
was not impaired compared to those with T2-3 tumors. A function preserving 
approach should be first choice for every patient with a larynx carcinoma, patients 
with selected T4 tumors included. However, surgery is probably a better alternative 
for cases with extensive cartilage destruction and tumor spread into the soft tissues 
of the neck where poor functional outcome is expected. Also patients who present 
with severe stridor while adequate endoscopic debulking is not possible are probably 
better served with laryngectomy (35). Merely the classification “T4” does not implicate 
that larynx preservation should be dismissed as treatment option. The current trial 
also demonstrated that local control rate for patients with T4 tumors was 73% at 5 
years, which was not significantly different from T2 and T3 tumors (17). Recently, 
several reports confirmed that laryngeal preservation, loco-regional control, and 
overall survival in patients with selected T4 tumors are similar to patients with less 
advanced primary tumors (36,37). 
Conclusion
Quality-of-life reports of patients with T2-4 larynx carcinoma were good after treatment 
with accelerated radiotherapy with or without carbogen and nicotinamide. AR and 
ARCON resulted in high local tumor control rates (± 80%) and a benefit of 8% in 
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regional control rate with ARCON. After both regimens excellent speech and 
swallowing function could be maintained for the majority of patients, selected 
T4-stages included. Long-term dry mouth, sticky saliva and changes in taste and 
smell were limited to one quarter of patients. Older age was associated with impaired 
recovery of swallowing function.
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General Discussion 
Functional larynx preservation is a main goal when treating patients with advanced 
laryngeal cancer. The purpose of this thesis was to investigate the addition of 
carbogen breathing and nicotinamide to accelerated radiotherapy (ARCON) in 345 
patients with advanced laryngeal cancer. 
Positive trial or negative trial?
The outcome of the randomized trial comparing accelerated radiotherapy alone with 
ARCON is described in Chapter 2. There was no significant difference in primary 
endpoint. In the experimental arm local control after 64 Gy was consistent with the 
80% local control rate obtained in the preceding phase II ARCON trial [1]. 
Unexpectedly, the local control rate with 68 Gy in the control arm (78%) was higher 
than the rates reported in retrospective studies at the time of onset of this study. This 
4 Gy absolute dose difference to the larynx, to reduce the risk of cartilage damage, is 
a likely explanation for the lack of additional benefit in local control with ARCON 
compared to AR. In fact, it supports the enhancing effect of ARCON for local tumor 
control as similar local control is obtained with a lower radiotherapy dose. In both 
treatment arms pathologic lymph nodes did receive a same dose of 68 Gy. A benefit 
of 8% in regional control rate was observed in favor of ARCON. This finding is 
consistent with the results of a recent systematic review and meta-analysis of hypoxia 
modification in head and neck cancer in which an absolute risk reduction of 8% for 
loco-regional control was observed [2]. 
Five-year larynx-preservation rates of AR and ARCON were 84% and 87%, respectively 
and equivalent to the 84% observed in the RTOG 91-11 trial with a combination of 
conventional radiotherapy and concurrent cisplatin 100 mg/m2 on days 1,22 and 43 
[3]. Unfortunately, no adaptation in study design was performed when the outcome 
of the RTOG 91-11 trial was published in 2003 [4]. As no randomized comparison 
between AR, ARCON and concurrent radiotherapy with cisplatin for laryngeal cancer 
is available today, the combination of conventional radiotherapy with concomitant 
cisplatin remains the standard for patients with advanced laryngeal cancer.
Toxicity 
Although pre-clinical and phase I and II trials do suggest an enhancement of acute 
reactions with ARCON, a similar acute toxicity profile for skin and mucosa-associated 
symptoms is observed for both regimens. A likely explanation for this observation is 
the lower boost dose to the larynx in patients treated with ARCON (64 Gy vs 68 Gy) 
to decrease the risk of cartilage damage. Strikingly, the median duration of confluent 
mucositis for the ARCON regimen in the multi-center phase III trial was limited to a 
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median of 3 weeks which is only half of what was observed in previous trials [5,6]. 
Given the large number of patients enrolled from Nijmegen (N=144/345), a subgroup 
analysis was performed. In this subgroup, a median duration of confluent mucositis 
of 5.0 weeks (versus 2.0 weeks in other centers, P= <.01) was observed, suggesting 
that significant inter-observer and inter-institutional variations in toxicity scoring do 
exist. It is important to be aware of this phenomenon when interpreting data from 
multi-center studies and this problem is probably of even greater relevance for late 
toxicity [7]. 
Full compliance with carbogen breathing and nicotinamide intake was high. Despite, 
a number of patients treated with ARCON experienced discomfort with the breathing 
procedure and digestive troubles due to nicotinamide intake, difficult to manage with 
adjustment of anti-emetics. This resulted in a discontinuation of carbogen breathing 
and nicotinamide intake for 6% and 12% of patients, respectively. It should be noted 
that the current study does not give evidence of the benefit for the use of ARCON 
compared to accelerated radiotherapy and carbogen breathing alone. Whether 
outcome is improved by the use of nicotinamide will need a three-armed study to 
decide (radiotherapy alone, radiotherapy with carbogen and radiotherapy with 
carbogen and nicotinamide). Analysis of late radiation morbidity did not reveal 
significant differences between AR and ARCON. All patients who developed a 
cartilage necrosis could be managed conservatively. Four patients received a 
tracheostomy (AR, n=1; ARCON: n=3), and there was no need for laryngectomy. This 
incidence corresponds to the 1-2% of cartilage damage seen in literature. Swallowing 
limited to soft foods and liquid is less frequently observed with AR or ARCON 
compared to radiotherapy with concomitant cisplatin [4]. Although direct comparison 
is difficult because of potential bias, a possible explanation can be the higher number 
of supraglottic tumors and the planned neck dissection in case of cN2a or cN2b 
tumors. Neck dissection after chemoradiotherapy has been demonstrated to increase 
the risk of long-term dysphagia and laryngeal dysfunction [8].
Health related Quality-of-life 
Treatment intensification has the potential to increase toxicity [8]. A balanced deci-
sion-making between increased toxicity and modest improvements in tumor control 
is often difficult for patients and treating physicians. So, proper knowledge of Health 
related quality-of-life (HRQoL) is essential to understand the real benefit of any new 
regimen. For this reason The European Organisation for Research and Treatment of 
Cancer (EORTC) Questionnaire-C30 (QLQ-C30) and the Head&Neck cancer module 
(QLQ-H&N35) was integrated in the ARCON phase III study. Similar changes in 
HRQoL were observed for both treatment arms: after a transient period of clinically 
significant impairment for the majority of items, a return to baseline levels was 
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observed after 6 months for nearly all items with exception of dry mouth, and 
associated symptoms of sticky saliva and altered taste and smell.  
The primary goal of radiotherapy for advanced laryngeal cancer is to preserve 
speech and swallowing. At 2 years from diagnosis, the majority of patients treated in 
the current trial had no or just few complaints of speech whereas the percentage of 
patients with severe problems was less than 15%. A lower percentage of patients with 
severe problems of speech is observed for patients treated with radiotherapy and 
concomitant cisplatin within the RTOG 91-11 trial [3,4]. However, this difference might 
be explained by the use of a different questionnaire and/or a higher rate of glottic 
tumors in the ARCON trial. Further, 80% of patients treated in the ARCON phase III 
study reported no or just a little complaints of swallowing and only 5% used a feeding 
tube at 2 years from diagnosis. The RTOG-study 90-03 compared different radiotherapy 
fractionation regimens and reported a 13% rate of tube feeding dependence after 
accelerated radiotherapy in a cohort of patients with head and neck cancer of various 
subsites [9]. In both RTOG and ARCON trials conventional 3D radiotherapy techniques 
were used. There is increasing evidence that modern high-precision radiotherapy 
techniques will result in a further improvement of functional outcome, by reducing the 
radiation dose to uninvolved swallowing structures [10,11].
Patient selection for hypoxia-modifying therapy
Evidence suggests that hypoxic tumors benefit most from hypoxia-modifying therapy 
[12-14]. In a translational side-study of the ARCON trial the value of pimonidazole, an 
exogenous marker for tumor hypoxia, was assessed. Regional control in the group 
with a high hypoxic fraction was significantly improved with ARCON compared to AR 
(100% vs. 55%; P= .01), whereas no difference between the treatment arms was 
observed in the group with a low hypoxic fraction. A trend towards a better overall 
survival was observed for patients with hypoxic tumors in the ARCON arm (P= .08). 
This predictive value of pimonidazol is in line with previous observations by Kaanders 
et al. [12]. 
Several other strategies of patient selection for hypoxia-modifying treatments have 
been attempted over the last years. The DAHANCA-5 trial found that the hypoxia ra-
diosensitiser nimorazole significantly improved outcome of radiotherapy for patients 
with all subtypes of head and neck cancer compared to placebo [13]. In a translational 
side-study the value of osteopontin, an endogenous marker for tumor hypoxia, was 
assessed. Loco-regional control and disease specific survival in patients with high 
osteopontin plasma levels was significantly improved with nimorazole compared to 
placebo. Unfortunately, no correlation between high levels of osteopontin and inferior 
outcome was observed in the TROG 02-02 phase III trial, randomizing patients with 
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stage III/IV head and neck cancer to radiotherapy and concomitant cisplatin or 
cisplatin plus tirapazamine, a hypoxic cell cytotoxin [15]. The same trial also failed to 
demonstrate a benefit of hypoxia modification in an unselected group of patients [16]. 
However, an interesting substudy provided evidence of a correlation between hypoxia 
on FMISO-PET-imaging and loco-regional failure [14]. Loco-regional failure in patients 
with hypoxic tumors receiving cisplatin/fluorouracil was significantly higher compared 
to patients receiving cisplatin plus tirapazamine. 
Approaches using multiplex markers such as gene signatures potentially better 
reflect the complex cellular response to hypoxia and account for the intra-tumor 
heterogeneity of hypoxia [17,18]. Based on a 15-gene hypoxia classifier, only 
HPV-negative patients with hypoxic tumors participating in the DAHANCA-5 trial 
profited from the addition of nimorazole. This resulted in a significantly better 
loco-regional control and disease-specific survival [17,19]. More recently, Eustace et 
al. used a 26-gene hypoxia signature in a cohort of 157 patients with T2-T4 laryngeal 
cancers treated in the phase III ARCON trial [18]. High expression (>median) was 
associated with a significant improvement in regional control when treated with 
radiotherapy plus hypoxia modification versus radiotherapy alone. Evaluation of 
these findings within a prospective trial is needed. 
Tumor volume 
Several retrospective studies demonstrate that the macroscopic primary tumor 
volume, as calculated from pre-treatment CT-scan or MRI, correlates with local 
control in patients with head and neck cancer treated with definitive (chemo)
radiotherapy [20-23]. The University of Florida repeatedly demonstrated that tumors 
with pre-treatment CT-based volumes smaller than 3.5 cm3 for glottic and 6.0 cm3 for 
supraglottic tumors had a significantly better local control rate [24,25]. However, this 
strong prognostic factor of primary tumor volume was not confirmed in patients 
treated with accelerated radiotherapy with or without carbogen breathing and 
nicotinamide. This study also failed to demonstrate a correlation between local tumor 
control and T-stage. One possible explanation for the absence of a volume-effect in 
the current study might be the reduction of overall treatment time by the use of 
accelerated radiotherapy. Larger tumors might be more hypoxic in absolute volume 
and more cancer stem cells might start repopulation after radiation induced 
re-oxygenation. Another important reason can be explained by the methodology: 
a large cohort of tumors was treated in a homogenous way by 3D-conformal 
radiotherapy in thermoplastic masks and position verification. Although tumor volume 
calculations in the retrospective studies are based on diagnostic CT- or MR-imaging, 
the radiotherapy planning was performed on conventional 2D equipment. It might 
be that larger tumors in particular are subjective to local failures by underestimating 
502026-L-sub01-bw-Janssens
119
General discussion and future perspectives 
7
tumor extension due to 2D-treatment planning and lack of position verification 
systems.   
 
Less data are available with respect to the volume of involved lymph nodes and nodal 
control in head and neck cancer. Although the presence of pathological lymph nodes 
in the current study was a poor prognostic factor for regional control, no correlation 
between total nodal volume and regional control was observed in both treatment 
arms. This could be explained by the high regional control rates and the limited 
number of events. To increase the study size and number of events, an additional 
analysis per individual lymph node was performed. This time, an inferior 5-year nodal 
control rate was observed in both treatment arms for increasing nodal volumes. The 
additional analysis also demonstrated that ARCON improved nodal control compared 
to accelerated radiotherapy alone independently of nodal volume. This observation 
supports the idea of hypoxia as a cause of regional failure. In contrast, no benefit of 
regional control was observed in the DAHANCA 6&7 trial by increasing the number of 
fractions per week from 5 to 6, suggesting only a minor contribution of repopulation 
in the neck nodes [26]. 
T4 tumors?
In patients with T4 tumors, anticipated poor functional outcome and lower expected 
disease control are common reasons to prefer laryngectomy instead of (chemo)
radiotherapy. However, based on our data on local control, long-term speech and 
swallowing, outcome of patients presenting with T4 tumors was not impaired 
compared to T2-3 tumors. Of course, there is a selection bias in the T4-category as 
patients with severe stridor, without adequate endoscopic debulking options, were 
excluded. Expert opinion says that surgery is probably a better alternative for cases 
with extensive cartilage destruction and tumor spread into the soft tissues of the neck 
where poor functional outcome is expected [27]. Nevertheless, “T4” does not 
implicate that larynx preservation should be dismissed as treatment option.
Anemia
Low pre-treatment hemoglobin levels are a strong prognostic indicator of poor 
disease control and survival in patients presenting with head and neck cancer [28]. 
Randomized trials failed to demonstrate outcome improvement with transfusions, 
and erythropoietin was even counterproductive [29-31]. The same observations are 
done in the current study for patients treated with accelerated radiotherapy alone. 
However, the impaired outcome of patients with anemia is no longer observed when 
carbogen and nicotinamide are added to accelerated radiotherapy. This observation 
is in line with an earlier proposed hypothesis from the ARCON phase II trial [32]. 
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The success of ARCON for patients with anemia can be explained by the so-called 
“reduced cord radius” [33]. The thickness of the tumor cord radius, being a blood 
vessel and its dependent tumor cell volume, decreases under anemic conditions 
[34]. Correction of hemoglobin levels by blood transfusion or erythropoietin will 
improve oxygenation of tumor cells in the peripheral zone of the cords. However, 
tumor cords will adapt and begin to proliferate and will once again outgrow their 
oxygen supply. As a consequence, the benefit of a blood transfusion is transient. In 
contrast, adaptive mechanisms do not occur with ARCON because the oxygenation 
increase is too short and only for the duration of the radiation treatment. Shorter 
oxygen diffusion distances and higher levels of free oxygen in plasma explain how 
ARCON can exploit adaptive mechanisms in patients with anemia.    
There are a number of hypotheses why patients with anemia have an inferior outcome 
compared with patients without anemia. It is assumed that impaired tumor oxygenation 
results in a more aggressive and treatment resistant tumor phenotype [35]. Correlations 
were found between hemoglobin level and tumor hypoxia, measured by pO2 
electrodes, particularly in patients with severe anemia [35-37]. In the current study, 
however, no correlation was found between hemoglobin and tumor hypoxia, as 
measured by pimonidazole binding. Albeit that there was only one patient with severe 
anemia in our study, this observation is consistent with the assertion that distribution, 
as function of the distance to the vessels, and not the absolute amount of hypoxia is 
relevant for the response to ARCON. Another reason for the poor prognosis of 
patients with anemia can be anaerobic glycolysis. Anemic patients have decreased 
blood viscosity and increased plasma flow. The greater availability of glucose will fuel 
the process of malignant progression as many tumors rely on glycolysis. This can 
explain the observation of an association between anemia and the trend toward a 
higher N-stage in this study. Apart from a causative factor, anemia might also be an 
epiphenomenon of aggressive tumor behavior. Cytokines inhibit erythropoiesis, 
affect the life span of erythrocytes and impair iron metabolism [37]  
Future perspectives
The addition of carbogen breathing and nicotinamide to accelerated radiotherapy 
produced a significant gain in outcome for a subgroup of patients with advanced 
laryngeal cancer. Furthermore, ARCON produced equal levels of toxicity and Quality- 
of-life compared to accelerated radiotherapy alone. Patients presenting with (larger) 
pathological lymph nodes and a high hypoxic fraction on pimonidazol staining or 
patients with pre-treatment anemia profit most of ARCON. Before implementation in 
daily practice, these findings need to be evaluated in a randomized clinical trial. 
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However, a number of reasons (e.g. the development of hypoxia gene signatures, 
lack of a universal measure of clinical hypoxia, new targeted therapies, best standard 
treatment arm, financial and political issues,…) have thus far hampered the 
development of a prospective trial.
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Summary 
Hypoxia (the lack of oxygen) and tumor cell repopulation are two important mechanisms 
of radiotherapy resistance in head and neck cancer. In this thesis the addition of 
hypoxia modification to accelerated radiotherapy was investigated as a treatment for 
advanced laryngeal cancer. From 2001 till 2008, 345 patients with cT2-4 laryngeal 
cancer were randomly assigned to accelerated radiotherapy (AR) or accelerated 
radiotherapy combined with carbogen breathing and nicotinamide (ARCON). 
Outcome, toxicity profile, role of anemia, impact of tumor volume and quality-of-life 
were evaluated. 
Chapter 1 is the general introduction to this thesis. Since the early nineties, functional 
larynx preservation is the preferred treatment for patients with advanced laryngeal 
cancer. However, a significant subset of patients will develop a loco-regional disease 
recurrence. Tumor cell repopulation and hypoxia are considered important mechanisms 
of therapy failure. Although during a course of radiotherapy the number of tumor cells 
with clonogenic potential is greatly reduced, cells that survive are triggered to 
repopulate more effectively. In addition, impaired blood perfusion and increased 
diffusion distances due to a chaotic vascular system within tumors will result into 
large temporal and spatial variability in tumor oxygenation, and consequent hypoxic 
radioresistance. ARCON has been developed to counteract repopulation by delivering 
several radiotherapy fractions per day, and hypoxia by inhalation of a hyperoxic gas 
and administration of nicotinamide to decrease diffusion- and perfusion-limited 
hypoxia, respectively. This chapter focuses on the effect of carbogen breathing and 
nicotinamide observed in preclinical studies using mouse mammary tumors. 
Phase I studies demonstrated the feasibility of ARCON. In a large phase II trial local 
control rates of 80% were observed for advanced-laryngeal cancers. The high local 
control rate for advanced laryngeal cancers, approaching the results reported for T1 
and T2 lesions, supported the concept of increased susceptibility of tumors to the 
biologically based approach of ARCON. However, large heterogeneity in biological 
characteristics does exist between tumors of the same site and histology. For this 
reason, markers of proliferative activity (Ki-67) and oxygenation status (e.g. pimonidazole, 
CAIX) in tumors become important and are discussed as a potential approach to 
select candidates for ARCON.
Chapter 2 reports on the outcome of the randomized trial. Patients with T2 glottic 
carcinoma with impaired cord mobility or subglottic extension, T2 supraglottic 
carcinoma with invasion of the mucosa of the base of tongue or vallecula or invasion 
of the medial wall of the piriform sinus, T3-4 glottic or supraglottic carcinoma at any 
502026-L-sub01-bw-Janssens
128
N-stage were eligible. A dose of 68 Gy in 34 fractions of 2 Gy over 5.5 weeks was 
prescribed to the primary tumor and macroscopic involved lymph nodes. To limit the 
risk of laryngeal necrosis, ARCON patients received 64 Gy on the laryngeal cartilage. 
The primary endpoint of the study was local control. After a median follow-up of 
44 months, local tumor control rate at 5 years was 78% for AR vs. 79% for ARCON 
(P= .80), with larynx preservation rates of 84% and 87%, respectively (P= .48). The 
5-year regional control was significantly better with ARCON compared to AR (93% vs. 
86%, P=.04). In a translational side study, the hypoxia marker pimonidazole was used 
to assess the oxygenation status in tumor biopsies. The improvement in regional 
control was specifically observed in patients with hypoxic tumors and not in patients 
with well-oxygenated tumors (100% versus 55% respectively, P= .01). Thus, despite 
lack of benefit in local control, a significant gain in regional control was observed with 
ARCON. Translational research using a hypoxia marker assay demonstrated that 
proper patient selection is key to the success of this approach.
Acute toxicity was scored weekly from baseline until week 8 plus every 2-4 weeks 
thereafter and described in Chapter 3. Between both treatment arms (AR vs. ARCON) 
no statistically significant difference was observed for incidence of acute skin 
reactions (moist desquamation: 56% vs. 58%, P= .80), acute mucosal reactions 
(confluent mucositis: 79 vs. 85%, P= .14) and symptoms related to mucositis (severe 
pain on swallowing: 53% vs. 58%, P= .37; nasogastric tube feeding: 28% vs. 28%, P= 
.98, narcotic medicines required: 58% vs. 58%, P= .97). Although statistically 
significant, the median duration of confluent mucositis was only slightly different in 
favor of AR (2.0 vs 3.0 weeks, P= .01). There was full compliance with carbogen 
breathing and nicotinamide in 86% and 80% of the patients with discontinuation in 
6% and 12%, respectively. Adjustment of anti-emesis prophylaxis was needed in 42% 
of patients. These observations provided a convenient base for determination of the 
real therapeutic benefit of ARCON. 
In Chapter 4, the outcome of a subgroup of 54 patients, participating in the phase III 
trial, who presented with anemia is discussed. From literature, it is well known that 
anemia is associated with poor tumor control and prognosis. Previously, it was 
demonstrated in retrospective analyses that ARCON can correct this adverse 
outcome in patients with head and neck cancer. Pretreatment hemoglobin levels 
were available and below normal in 27/173 and 27/167 patients treated with AR and 
ARCON, respectively. In patients with normal pre-treatment Hb-levels, treatment with 
ARCON had no significant effect on 5-year loco-regional control (79% vs. 75%, P= 
.44) and disease-free survival (75% vs. 70%, P= .46) compared to AR. However, in 
patients with low pre-treatment Hb-levels ARCON significantly improved 5-year 
loco-regional control (79% vs. 53%, P= .03) and disease-free survival (68% vs. 45%, 
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P= .04). In multivariate analysis including other prognostic factors, pre-treatment Hb 
remained prognostic for loco-regional control and disease-free survival in the AR 
treatment arm. No correlation was observed between pre-treatment Hb-levels and 
pimonidazole uptake in tumor biopsies. The observation of improved outcome in 
patients with anemia supported previous findings from the phase II ARCON trial. 
However, the potential of ARCON to correct the poor outcome of patients with anemia 
should be further explored and validated in a randomized trial with focus on patients 
presenting with anemia. 
Retrospective studies indicate that larger tumor volume is a strong prognostic 
indicator for poor tumor control after (chemo)radiotherapy for laryngeal cancer. The 
impact of tumor volume on the outcome of patients with locally-advanced laryngeal 
cancer treated in the phase III ARCON trial was investigated in Chapter 5. 
Pre-treatment CT-scans of 270 patients were available for tumor volume calculation. 
Contouring of the primary tumor and involved lymph nodes was reviewed. Of 137 and 
133 treated with AR or ARCON, 57 and 80 vs. 56 and 77 patients had glottic and 
supraglottic tumors, respectively. A correlation between primary tumor volume and 
T-stage was observed (Rs= .51, P= <.01). In neither of the treatment arms a 
correlation was detected between the primary tumor volume and local control, 
regional control or metastasis-free survival. A strong correlation between total nodal 
volume and N-stage was found (Rs= .93, P= <.01). Both in the AR and ARCON 
groups total nodal volume was not associated with poorer regional control rate. 
However, based on individual lymph node analysis, nodal control was in favor of 
ARCON, irrespective of volume (P= <.01). The strong prognostic value of primary 
tumor volume, observed in a number of retrospective analyses was not confirmed in 
patients treated in this prospective randomized trial with 3D-conformal, accelerated 
radiotherapy ± carbogen breathing and nicotinamide. In patients with pathological 
lymph nodes, a correlation between total nodal volume and regional control was 
lacking as well. Additional analyses based on individual nodal volumes demonstrate 
an excellent regional control rate and a significant benefit of ARCON.
Radiotherapy for patients with advanced laryngeal cancer has a significant impact on 
health-related quality-of-life (HRQoL), as reported in Chapter 6. The price of treatment 
intensification is a potential increase of acute and long-term toxicity. Between AR and 
ARCON, no difference in toxicity has been observed. However, proper knowledge of 
HRQoL is equally essential to understand the real benefit of this new regimen. For this 
reason, HRQoL was assessed using the European Organisation for Research and 
Treatment of Cancer (EORTC) HRQoL Questionnaire-C30 (QLQ-C30) and the Head 
& Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and 
at 6, 12, and 24 months post-baseline. Moderate to severe clinical impact of the 
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treatment was observed for nearly all items of the QLQ-C30 and QLQ-H&N35 
between baseline and end of treatment. Again, no difference in HRQoL score 
between AR and ARCON was observed. At 6 months, scores returned to baseline 
level with exception of dry mouth, sticky saliva, and taste/smell. At 2 years from 
baseline, the percentage of patients reporting moderate to severe complaints of dry 
mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 18%, respectively 
while the majority of patients had no or few complaints of swallowing (79%) or speech 
(64%). The use of a feeding tube at 2 years from diagnosis was limited to 5% of 
patients. It was concluded that HRQoL reports were similar with AR or ARCON. After 
both regimens excellent speech and swallowing function could be maintained for the 
majority of patients, selected T4-stages included. Long-term dry mouth, sticky saliva 
and changes in taste and smell were limited to one quarter of patients. 
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Samenvatting 
Hypoxie (zuurstofgebrek) en tumor cel repopulatie zijn twee belangrijke mechanismen 
die de kans op recidief na radiotherapie voor een tumor van het hoofdhals gebied 
kunnen vergroten. In dit proefschrift werd de rol van hypoxie correctie onderzocht bij 
de behandeling van het gevorderd larynx carcinoom. Tussen 2001 en 2008 werden 
345 patiënten met een cT2-T4 larynx carcinoom gerandomiseerd tussen enerzijds 
geaccelereerde radiotherapie (AR), anderzijds geaccelereerde radiotherapie in 
combinatie met inhaleren van carbogen gas (98% O2 + 2% CO2) en slikken van 
capsules met nicotinamide (ARCON). De uitkomst, het toxiciteitsprofiel, de rol van 
anemie, de bijdrage van het tumorvolume  en de levenskwaliteit werden onderzocht. 
Hoofdstuk 1 omvat de algemene inleiding tot dit proefschrift. Sinds enkele decennia, 
is het behoud van spraak- en slikfunctie een primair streven bij patiënten met een 
gevorderd larynxcarcinoom. Desalniettemin zal een aanzienlijk aantal patiënten tijdens 
de eerste jaren na bestraling toch ziekterecidief ontwikkelen. Repopulatie van de tumor 
cellen en hypoxie worden beschouwd als belangrijke onderliggende mechanismen 
voor het falen van deze behandeling. Hoewel het aantal tumor cellen dat in staat is 
om te delen tijdens de bestraling afneemt, is bekend dat overlevende tumor cellen 
geprikkeld worden om sneller te gaan delen. Daarnaast is een tumor opgebouwd uit 
een chaotisch kluwen van bloedvaten. Verminderde perfusie en toegenomen diffusie 
afstanden zorgen voor een belangrijke variatie qua tumor oxygenatie in tijd en ruimte, 
met hypoxie gerelateerde resistentie als gevolg. ARCON werd destijds ontwikkeld 
om beide mechanismen te neutraliseren: repopulatie door middel van het geven van 
meerdere bestralingsfracties per dag en hypoxie door inhaleren van carbogen en slikken 
van tabletten met nicotinamide om respectievelijk diffusie- en perfusie-gerelateerde 
hypoxie op te heffen. 
Dit hoofdstuk behandelt kort het effect van carbogen en nicotinamide in preklinische 
studies. Aansluitend volgen de klinische data. Fase-1 studies toonden de haalbaarheid 
van ARCON. In een grote fase-2 studie werd met ARCON een lokale controle van 
80% bekomen bij patiënten met gevorderde larynxcarcinomen. Een controle percentage 
bij gevorderde larynxtumoren dat het resultaat van kleine larynxcar cinomen (cT1-T2) 
benaderde, maakte het larynxcarcinoom een geschikte tumorsite voor biologisch 
gestuurd onderzoek middels een fase-3 studie. Wat de biologische kenmerken 
betreft, is het welbekend dat er tussen tumoren van eenzelfde tumorsite en histologie 
een grote spreiding kan voorkomen. Markers gerelateerd aan tumor proliferatie 
(Ki-67) en oxygenatie (pimonidazole, CAIX) worden besproken als mogelijke factoren 
om de geschikte kandidaat voor een therapie met ARCON te selecteren.           
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Hoofdstuk 2 rapporteert de uitkomst van de fase-3 studie. Patiënten met een T2 
tumor van de ware stemband met verminderde beweeglijkheid van een larynxhelft of 
uitbreiding in de subglottis, T2 supraglottis tumoren met invasie van het slijmvlies van 
de tongbasis of vallecula of mediale zijde van de sinus piriformis, alsook T3-4 glottis 
of supraglottis carcinomen, onafhankelijk van de N-status, waren geschikt voor 
randomisatie. Op de primaire tumor en de aangedane klieren werd een dosis van 68 
Gy in 34 fracties van 2 Gy over een periode van 5.5 weken gegeven. Teneinde het 
risico op larynx necrose te beperken, werd bij patiënten behandeld met ARCON de 
dosis op de primaire tumor gereduceerd tot 64 Gy. Lokale controle was het primaire 
eindpunt van de studie. Met een mediane follow-up van 44 maanden, bedroeg de 
lokale controle na 5 jaar 78% voor AR en 79% voor ARCON (P= .80) en het larynx 
preservatie percentage respectievelijk 84% en 87% (P= .48). De regionale controle 
na 5 jaar toonde een significant verschil ten voordele van ARCON (93% vs. 86%; 
P= .04). Om de oxygenatie status te bepalen van de primaire tumor werd de hypoxie 
marker pimonidazole gebruikt. Translationeel onderzoek liet een significant voordeel 
in regionale controle zien bij patiënten met hypoxische tumoren die behandeld 
werden met ARCON (ARCON vs. AR: 100% vs. 55%, P= .01). Bij tumoren zonder 
hypoxie werd geen winst van ARCON aangetoond. Samengevat, ondanks het 
ontbreken van winst in lokale controle, werd een significant verschil in regionale 
controle aangetoond bij patiënten behandeld met ARCON. Het gebruik van een 
hypoxie marker is essentieel om de ideale kandidaat voor een behandeling met 
ARCON te selecteren. 
De acute toxiciteit werd wekelijks gescoord vanaf aanvang behandeling tot week 8, 
aansluitend iedere 2-4 weken, en werd beschreven in hoofdstuk 3. Tussen beide 
behandelarmen (AR vs. ARCON) werd geen significant verschil aangetoond qua 
huidreacties (nattende desquamatie: 56% vs. 58%, P= .80), slijmvliesreacties 
(confluente mucositis: 79% vs. 85%, P= .14) of symptomen gerelateerd aan de slijm-
vliesreacties (ernstige pijn bij slikken: 53% vs. 58%, P= .37; voeding via 
neusmaagsonde: 28% vs. 28%m P= .98; gebruik opioiden: 58% vs. 58%, P= .97). 
Hoewel statistisch significant, bedroeg het verschil in mediane duur van de confluente 
mucositis slecht 1 week (AR vs. ARCON: 2.0 vs. 3.0 weken, P= .01). Volledige 
compliantie met het inhaleren van carbogen en slikken van nicotinamide tabletten 
bedroeg respectievelijk 86% en 80% terwijl het stopzetten van deze middelen slechts 
bij 6% en 12% van de patiënten werd geobserveerd. Aanpassing van anti-emetica 
profylaxe was noodzakelijk voor 42% van de patiënten. Kortom, het ontbreken van 
een significant verschil in acute toxiciteit vormt een goede basis om de echte winst 
van ARCON te beoordelen. 
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Hoofdstuk 4 laat de uitkomst zien van 54 patiënten met anemie bij diagnose, 
behandeld in de fase-3 ARCON studie. Publicaties hebben herhaaldelijk aangetoond 
dat anemie geassocieerd is met een slechtere lokale controle en prognose. Een 
eerder uitgevoerde retrospectieve analyse van patiënten met een tumor in het 
hoofdhals gebied, liet echter zien dat deze inferieure prognose gecorrigeerd kan 
worden met ARCON. In de fase-3 studie was het hemoglobine (Hb)-gehalte bij 
diagnose bekend en te laag bij 27/173 en 27/167 patiënten behandeld met respecti-
evelijk AR en ARCON. Bij patiënten met normale Hb-waarden voor de start van de 
behandeling, werd qua locoregionale controle (79% vs. 75%, P= .44) en ziektevrije 
overleving (75% vs. 70%, P= .46) na 5 jaar geen effect gezien van ARCON, vergeleken 
met AR. Daarentegen werd bij patiënten met een laag Hb bij diagnose en behandeld 
met ARCON een significante winst in locoregionale controle (79% vs. 53%, P= .03) 
en ziektevrije overleving (68% vs. 45%, P= .04) gezien na 5 jaar. Bij multivariate 
analyse bleef het Hb-gehalte bij diagnose in de AR-arm zijn prognostische waarde 
voor locoregionale controle en ziektevrije overleving behouden. Er werd geen 
correlatie aangetoond tussen het Hb-gehalte bij diagnose en de pimonidazole 
opname in de biopten.  Het aantonen van winst in locoregionale controle en ziektevrije 
overleving bij patiënten met anemie bevestigt eerdere bevindingen uit de fase-2 
ARCON studie. Deze potentieel corrigerende rol van ARCON dient verder te worden 
onderzocht en gevalideerd in een gerandomiseerde studie, gericht op patiënten met 
anemie bij diagnose.
Uit retrospectieve studies bleek het volume van een larynxtumor een prognostische 
factor te zijn voor tumor controle na radiotherapie ± chemotherapie. Hoofdstuk 5 
beschrijft de impact van het tumorvolume op de uitkomst van patiënten met een 
gevorderd larynxcarcinoom en behandeld in de ARCON fase-3 studie. Bij 270 
patiënten uit deze studie was een CT-scan bij diagnose beschikbaar om het 
tumorvolume te berekenen. De intekening van de primaire tumor en de aangedane 
klieren werd nagekeken. In deze groep waren respectievelijk 137 en 133 patiënten 
behandeld met AR of ARCON, en hadden 57 en 80 versus 56 en 77 patiënten een 
glottis of supraglottis tumor. Een correlatie tussen het primaire tumorvolume en het 
T-stadium werd aangetoond (Rs= .51, P= <.01). In geen van beide studiearmen 
werd een correlatie aangetoond tussen het primaire tumorvolume en de lokale 
controle, regionale controle of metastasevrije overleving. Eveneens werd een sterke 
correlatie aangetoond tussen het totale kliervolume en de N-status (Rs= .93, P= 
<.01). Het totale kliervolume was in beide studiearmen evenmin geassocieerd met 
de regionale controle. Echter, bij analyse van de individuele klieren werd, ongeacht 
tumorvolume, bij patiënten behandeld met ARCON een significante winst gezien wat 
betreft controle van pathologische klieren (P= <.01). Kortom, het tumorvolume als 
prognostische factor, aangetoond in meerdere retrospectieve studies, werd niet 
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bevestigd in deze prospectief gerandomiseerde studie met geaccelereerde radiotherapie 
± carbogen-nicotinamide en 3D-conformele planning. Bij patiënten met pathologische 
klieren ontbrak eveneens een correlatie tussen het totale kliervolume en de regionale 
controle. Aanvullende analyse gericht op individuele kliervolumes liet bij patiënten 
behandeld met ARCON een uitstekende regionale controle en een significante winst 
zien vergeleken met AR.   
De impact van een bestralingsbehandeling, voor een gevorderd larynxcarcinoom, op 
de levenskwaliteit van patiënten wordt beschreven in hoofdstuk 6. Intensivering van 
een behandeling zoals ARCON kan echter een toename van acute en late schade 
betekenen. Vooralsnog werd tussen AR en ARCON geen verschil in toxiciteit 
geobserveerd. Meer kennis van de levenskwaliteit was echter noodzakelijk om de 
reële winst van een nieuwe therapie te begrijpen. Om die reden werden bij diagnose, 
bij het einde van de radiotherapie en 6,12 en 24 maanden na aanvang therapie twee 
EORTC-vragenlijsten (QLQ-C30 en QLQ-H&N35) ingevuld. Tussen start en einde 
van de radiotherapie werd een matige tot ernstige impact op nagenoeg alle items van 
beide vragenlijsten geobserveerd. Tussen AR en ARCON werd geen verschil in lev-
enskwaliteit aangetoond. Zes maanden na aanvang therapie werd, met uitzondering 
van een droge mond, kleverig speeksel en een vreemde smaak/geur beleving, een 
normalisatie tot uitgangswaarde gezien. Twee jaar na de start van de behandeling 
bedroeg het percentage patiënten met matige tot ernstige klachten van droge mond, 
kleverig speeksel of vreemde smaak/geur beleving respectievelijk 30%, 22% en 18% 
terwijl de grote groep patiënten geen of nauwelijks klachten ondervond met slikken 
(79%) of spreken (64%). Het gebruik van een neusmaagsonde, 2 jaar na diagnose, 
was beperkt tot 5% van de patiënten. We kunnen concluderen dat er geen verschil in 
levenskwaliteit werd aangetoond bij patiënten behandeld met AR of ARCON. Het 
merendeel van de patiënten vermeldde een uitstekende spraak- en slikfunctie, zo ook 
geselecteerde patiënten met T4-tumoren. Na 2 jaar ondervond slechts een kwart van 
de patiënten last van droge mond, kleverig speeksel en een vreemde smaak/ 
geurbeleving.
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Het behoud van de spraak- en slikfunctie is een essentieel streven bij patiënten met 
een gevorderde tumor van het strottenhoofd. Met behulp van radiotherapie kan in het 
merendeel van de gevallen genezing worden bereikt. Toch ontwikkelt een aantal 
patiënten een tumorrecidief. Zuurstof tekort in de tumor en toename van de delingss-
nelheid van de kwaadaardige cellen zijn twee onderliggende mechanismen die de 
kans op tumorrecidief beïnvloeden. Om de impact van zuurstoftekort bij patiënten 
met een gevorderde tumor van het strottenhoofd in kaart te brengen werd een 
internationale studie opgezet. Patiënten kregen radiotherapie of radiotherapie met 
toevoegen van zuurstof (ademen van carbogen en slikken van tabletten met nicotin -
amide) als behandeling aangeboden. Ziektecontrole, bijwerkingen, invloed van bloed - 
armoede, bijdrage van tumorvolume en levenskwaliteit bij deze behandelingen werden 
in dit proefschrift onderzocht. Dit onderzoek liet zien dat de kans op ziekterecidief 
in de klieren aanzienlijk kleiner wordt door toevoegen van zuurstof terwijl geen extra 
bijwerkingen of een verschil in levenskwaliteit werden vastgesteld. Door voorafgaand 
aan de behandeling ook het zuurstofgehalte in de tumor te bepalen, is het mogelijk 
om deze patiënten te selecteren, die baat hebben bij het toevoegen van zuurstof. 
Verder liet dit onderzoek ook zien dat de toegenomen kans op tumorrecidief bij 
patiënten met bloedarmoede volledig gecorrigeerd kan worden door het toevoegen 
van zuurstof voor iedere behandeling. De kans op ziekterecidief in deze studie was 
niet beïnvloed door het tumorvolume.    
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